The Tumor-on-Chip: Recent Advances in the Development of Microfluidic Systems to Recapitulate the Physiology of Solid Tumors
Open accessThe DOI matches its Crossref record; 229 of the 231 references it cites were found in a registry or an index; 136 of the 207 sources its claims cite were checked for support.
Abstract
The ideal in vitro recreation of the micro-tumor niche-although much needed for a better understanding of cancer etiology and development of better anticancer therapies-is highly challenging. Tumors are complex three-dimensional (3D) tissues that establish a dynamic cross-talk with the surrounding tissues through complex chemical signaling. An extensive body of experimental evidence has established that 3D culture systems more closely recapitulate the architecture and the physiology of human solid tumors when compared with traditional 2D systems. Moreover, conventional 3D culture systems fail to recreate the dynamics of the tumor niche. Tumor-on-chip systems, which are microfluidic devices that aim to recreate relevant features of the tumor physiology, have recently emerged as powerful tools in cancer research. In tumor-on-chip systems, the use of microfluidics adds another dimension of physiological mimicry by allowing a continuous feed of nutrients (and pharmaceutical compounds). Here, we discuss recently published literature related to the culture of solid tumor-like tissues in microfluidic systems (tumor-on-chip devices). Our aim is to provide the readers with an overview of the state of the art on this particular theme and to illustrate the toolbox available today for engineering tumor-like structures (and their environments) in microfluidic devices. The suitability of tumor-on-chip devices is increasing in many areas of cancer research, including the study of the physiology of solid tumors, the screening of novel anticancer pharmaceutical compounds before resourcing to animal models, and the development of personalized treatments. In the years to come, additive manufacturing (3D bioprinting and 3D printing), computational fluid dynamics, and medium- to high-throughput omics will become powerful enablers of a new wave of more sophisticated and effective tumor-on-chip devices.
Overview
CoChat Summary
## TL;DR
This is a tutorial review of tumor-on-chip systems for solid-tumor research, arguing that microfluidic 3D models better recapitulate tumor physiology and dynamics than traditional 2D culture and many animal or static 3D models. It surveys recent device architectures and applications, especially spheroid models, co-cultures with stromal/healthy cells, vascularized chips, drug screening, nanoparticle transport, and precision-medicine uses.
## Key findings
- The paper states that less than 10% of anticancer drugs entering clinical trials reach the market, motivating more predictive preclinical models.
- Tumor-on-chip systems are presented as better than 2D culture because they can incorporate 3D architecture, dynamic flow, nutrients, and pharmaceutical compounds, and as more controllable than animal models, which are described as time-, resource-, and expertise-intensive and not fully human-relevant.
- In a 48-h perfused mesothelioma spheroid chip, spheroid morphology stayed essentially unchanged, but perfused spheroids showed higher chemoresistance to cisplatin than static spheroids; the system used about 5000 cells per assay.
- Several examples reported quantitative treatment or transport effects, including 100 nm nanoparticles penetrating better than 200 nm particles, DOX at 10 and 100 µg/mL destroying an endothelial barrier in one co-culture model, vessels in breast tumor compartments being 2.62-fold more permeable to nanoparticles than healthy-tissue vessels, and vascularized HCT116 microtumors showing one-order-higher chemoresistance to oxaliplatin than 2D monolayers.
## Methods
- Design: Narrative/tutorial review organized by increasing model complexity: simple spheroids, spheroids in hydrogels, non-spheroid cancer–normal co-cultures, vascularized systems, and precision-medicine applications.
- Data/sample: The review focuses on recent literature from 2011 onward on solid-tumor microfluidic systems and cites multiple representative device studies and model systems.
- Analysis: Comparative synthesis of published examples, emphasizing device architecture, fabrication/materials, flow and pressure control, and reported biological readouts such as drug response, nanoparticle transport, cell invasion, and vascular permeability.
## Limitations
- The paper states that the complete recapitulation of the true nature and evolution of a malignant tumor in vitro is challenging, and that high-fidelity 3D emulation remains an aspiration.
- It states that microfluidic device fabrication still requires skill and experience, and that better biomaterials, 3D printing, CFD, and omics will be needed for more advanced systems.
- Evident from the text: this is a review, not an original experimental study, so its conclusions depend on the quality and scope of the cited literature rather than new primary data.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Recapitulation of the tumor niche using tumor-on-chip systems with various degrees of sophistication. (a) The evolution of our cancer research tools—from 2D to 3D, and beyond—tumor-on-chip systems. Colored circles show the degree of fulfillment of different features. Green: fully fulfilled; Yellow: partially fulfilled; Red: poorly fulfilled; (b) Scheme of the tumor niche. Modified from Han et al., 2016 [19]. (c) Different types of tumor-on-chip systems: from simple spheroids in a microflow to vascularized and perfusable tumor microtissues [20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72].](https://figures.cochat.ai/paper-figures/c26bbf874804474397dc5dfe2bb673c9/the-tumor-on-chip-recent-advances-in-the-development-of-microfluidic-systems-to-figure-1.jpg)
![Figure 2 Architecture of tumor spheroids and their fabrication techniques. (a) Schematic representation of the 3D architecture of a tumor spheroid. Modified from Sant and Johnston 2017 [126]; (b) Fabrication of spheroids by the following scaffold-free methods: (i) hanging drop [122,127,128,129], (ii) liquid-overlay method [130,131,132,133,134,135,136], and (iii) force-driven method [129,132,137,138,139,140,141]; (c) Fabrication of spheroids by the following scaffold-based methods: (i) spheroids with a matrix-on top and embedded in a matrix [133,134,135], (ii) spheroids encapsulated within a molded matrix [142,143,144], and (iii) spheroids formed by suspending cancer cells within a liquid matrix and applying microfluidic-based strategies to form spheroids in droplets [119,145,146,147,148].](https://figures.cochat.ai/paper-figures/e54332efbd5643e0917a359371e47974/the-tumor-on-chip-recent-advances-in-the-development-of-microfluidic-systems-to-figure-2.jpg)
![Figure 3 Simple tumor-on-chip systems: a tumor spheroid continuously perfused within a microfluidic device. (a) Simple serpentine-shaped microfluidic system designed by Ruppen et al. [20], (i) designed to trap cancer cell agglomerates for fabrication of tumor spheroids. A simple hydraulic system enabled the trapping of cell agglomerates (scale bar: 10 μm) (ii) in small cavities. Once the upstream cavities were occupied by spheroids, flow was directed to downstream portions of the serpentine (scale bar: 500 μm) (iii) to favor new trapping events. (iv) Spheroids grew and matured in these cavities and were continuously exposed to anticancer compounds. Taken from reference [20]; (b) Microfluidic device developed by Huang et al. [21]: (i) general architecture, (ii) hydraulic testing, (iii) detail of the spheroid traps, and (iv) actual spheroid trapped in a holder as imaged in bright field. Schematic representation of the effect of (scale bar: 50 μm) (v) protein corona, and (vi) charge, on nanoparticle penetration into tumor spheroids. Taken from reference [21]; (c) Simple pump-independent (i) microfluidic system devised by Patra et al. [22] for continuous formation and perfusion of cancer spheroids (ii) contained within rectangular cavities located at the floor of the microfluidic circuit. (iii) Flow is driven simply by a pressure head induced by a difference in the height of the column of liquid (culture medium) between the inlet and the outlet reservoir. Taken from reference [22]; (d) Tumor-on-chip system developed by Chen et al. [177]: (i) Scheme of the physiological context aimed, (ii) and overall microfluidic architecture. (iii) 3D-render showing cancer cells retained within a horseshoe trap. Red and blue arrows indicate the flow fields within the system. (iv) Scheme of the architecture of the system (side view), (v) detail of the array of traps holding spheroids of consistent size, and (vi) size of spheroids after 14 days of culture. Scale bar: 200 μm. Taken from reference [177]; (e) The microfluidic system developed by Lim and Park [23] enables the exposure of cancer spheroids to anticancer drug gradients. (i) Scheme of the overall architecture of the device, (ii) detail of the cell-culture section, and (iii) close-up showing the geometry of each culture microwell. (iv) Experimental demonstration of the effective generation of gradients using injections of a fluorescent tracer. Taken from reference [23].](https://figures.cochat.ai/paper-figures/7970a8152adf491395a936fa18311833/the-tumor-on-chip-recent-advances-in-the-development-of-microfluidic-systems-to-figure-3.jpg)
![Figure 4 Tumor-on-chip in which a spheroid is embedded in a hydrogel. (a) Microfluidic system proposed by Albanese et al. [27]: (i) scheme of the optically accessible TOC, (ii) actual image of the spheroid within the microfluidic chamber (scale bar: 1000 μm). The tumor spheroid is lightly embedded in collagen. Scale bar: 100 μm. (iii) Interstitial volume exchange (residence time within a spheroid) as a function of the inlet flow rate (black squares); the corresponding interstitial flow rate is shown (red diamonds). (iv) Scheme and image of 40 nm PEG nanoparticles penetrating the spheroid and accumulating in the interstitial spaces (scale bar: 100 μm). (v) Larger nanoparticles (d = 110 nm) cannot penetrate the spheroid. Scale bar: 100 µm. (vi) Nanoparticle of different sizes [40 nm (red); 70 nm (blue); 110 (green), and 150 (blue)] exhibit different accumulation rates within spheroids. Nanoparticles were injected into the chamber at 50 mL/h; (b) The tumor on chip designed by Kwak et al. [28] aimed to recapitulate (i) the dynamics induced by the pressure gradient between the capillary and the lymphatic nets. (ii) Scheme (scale bar: 300 μm) and (iii) actual microdevice: cancer spheroids (indicated by arrows) develop within collagen in the central compartment by day 3. These spheroids, like actual tumors, express (iv) E-cadherin and (v) collagen IV. Scale bar: 50 µm. This system enables studies of accumulation of nanoparticles within tumors. (vi) Concentration of 100 nm particles at different distances of the capillary boundary (vii) Accumulation of nanoparticles as a function of matrix stiffness, (viii) interstitial pressure, and (ix) particles size. Taken from reference [28]; (c) TOC devised by Piotrowsky-Daspit [30] to study the effect of intra-tumor interstitial pressure on tumor invasiveness. (i) Schematic representation of the device; (ii) Micrographs showing an E-cadherin-GFP aggregate under a condition where the pressure gradient favors invasiveness (higher pressure at the tumor core). Modified from Piotrowsky-Daspit [30].](https://figures.cochat.ai/paper-figures/949525e8367d4789b57e35a88a0a5f66/the-tumor-on-chip-recent-advances-in-the-development-of-microfluidic-systems-to-figure-4.jpg)
![Figure 5 Tumor-on-chip (TOC) systems in which cancerous and normal microtissues share an interface. (a) Crosstalk between cancer cells and fibroblasts in a Y-shaped TOC: (i) scheme and (ii) actual device. (iii) Human mammary fibroblasts (HMF) and breast cancer (MCF10-DCIS) cells establish a cross-talk at the interface between the cancerous and normal microtissue sections. Scale bar: 30 µm. (iv) Circularity, roundness, and aspect ratio (AR) of MCF10-DCIS cancer cells as a function of their distance from the interface. (v) Image analysis characterization of invasiveness. Taken from reference [33]; (b) On-chip activation of stromal tissue by crosstalk with cancerous tissue [35]: (i) schematic representation of the device and (ii) actual micrographs of normal cells (expressing GFP) and cancer cells (expressing RFP). Scale bar: 100 μm. (iii) Time sequence showing cancer cell migration and invasion. Scale bars: 100 μm; (c) TOC system that recapitulates early stage breast cancer: (i) tumor-niche aimed. (ii) Schematic representation of the TOC system. (iii) Cytotoxicity against cancerous DCIS spheroids and normal epithelial cells at different feeding conditions: continuous administration of Paclitaxel through the lower channel (open triangles), batch administration of paclitaxel on normal epithelial cells (open circles), and negative control (squares). (iv) Change in the projected area of a DCIS spheroid treated with paclitaxel in the TOC (white bars) and untreated (black bars; ** p < 0.05) (v) Micrographs of DCIS spheroids at day 0, after three days of culture, and after three days of paclitaxel treatment. Scale bars: 100 μm; (d) TOC by Ayuso et al. [36] to recapitulate hypoxia and nutrient gradients within cancerous tissue: (i) schematic representation and (ii) actual device. Scale bar: 1 cm. (iii) Evolution of the cancer cell viability profiles, and (iv-v) hypoxia levels within the device. Scale bar: 400 μm Taken from reference [36].](https://figures.cochat.ai/paper-figures/a5f48478b57c401495df89942ff126f5/the-tumor-on-chip-recent-advances-in-the-development-of-microfluidic-systems-to-figure-5.jpg)
![Figure 6 Tumor-on-chip (TOC) systems that consider spheroids embedded in non-cancerous cell-laden-hydrogels. (a) Chemotaxis-driven assembly of endothelial barrier in a TOC platform [50]. Brightfield images of MCF7 spheroids co-cultured with human umbilical vein endothelial cells (HUVECs) (i) immediately after encapsulation, (ii) after three, and (iii) five days of culture. Scale bars: 200 μm. (iv) Evolution of HUVEC densities within different GelMA hydrogel zones 1 through 5 (zones are indicated on the oval inset). Zones are indicated within the inset. (v) Spheroid size as a function of culture time. Size was quantified as the projected area of the spheroid and normalized to its size at day 0; (*) and (**) indicate statistically significant differences of p < 0.05 and 0.01, respectively in a pairwise t-test. (vi) HUVECs and MCF7 spheroids (as observed in bright field) five (D5) and eight days (D8) after doxorubicin (DOX) treatment. Red arrows indicate the presence (or absence) of endothelial barrier. Scale Bar: 200 μm. (vii) MCF7 spheroid size after treatment with increasing doses of DOX. The spheroid area was normalized with respect to that of untreated spheroids. Significant differences are indicated by (*, **): p < 0.05 and 0.01, respectively (pair wise t-test). Taken from reference [50]; (b) TOC developed by Jeong et al. [51] to study the crosstalk and mutual activation between fibroblasts and cancer cells: (i) schematic of the device, (ii) and (iii) successive close-ups on the channel section, (iv) detail of the cell culture channel, and (iv) comparison of migration distances of fibroblasts in the direction of the cancerous region (blue) and the non-cancerous region (gray). (vi) Micrographs of cancer spheroids treated with different doses of DOX in monoculture and co-culture conditions. Scale bars: 50 μm. (vii) Evaluation of DOX efficacy in co-culture and monoculture conditions in this TOC. Significant differences are indicated by (*): p < 0.05. Taken from reference [51]; (c) TOC developed by Aref et al. [48], to model immune checkpoint blockade. (i) A real tumor is subjected to dissociation (mechanical and enzymatic) to yield dissociated tumor tissue (spheroids, cell agglomerates and single cells); (ii) schematic of Aref’s TOC; (iii) spheroid stained to reveal the presence of calcein AM (green); CD8 T cells (red); tumor cells (EpCAM; purple); and all nucleated cells (Hoechst; blue). Scale bars: 20 μm. (iv) Cell viability, and (v) cytokine expression profile over time in spheroids derived from patients and treated with different immunotherapies: α-PD-1: pembrolizumab, 250 μg mL−1); α -CTLA-4: (ipilimumab, 50 μg mL−1); or a combination. Taken from reference [48]. (d) TOC proposed by Bruce et al. [49] to recreate a bone marrow microenvironment and study acute lymphoblastic leukemia (ALL): (i) schematic representation, (ii) actual image, (iii) and detail of the post array within the device. (iv–vii) Confocal images of co-cultures of SUP-B15 (yellow arrows) and BMSC cells (white arrows) in (iv) 2D static, (v) 3D static, and (scale bars: 500 μm and 100 μm) (vi) 3D dynamic models. Proliferating cell nuclei were stained with Ki67 (green). Actin filaments were stained with phalloidin (red). Cell nuclei were stained with DAPI (blue). Scale bars: 20 μm. (vii) Chemoresistance of tumor cells to Ara-C among tri-culture or monoculture systems, in 2D versus 3D culture, and exposed (or not) to interstitial flow. (+) and (*) indicate significant difference between groups of p < 0.1, and p < 0.05, respectively. Taken from reference [49].](https://figures.cochat.ai/paper-figures/bf26efaa736246e18e74849343e0410f/the-tumor-on-chip-recent-advances-in-the-development-of-microfluidic-systems-to-figure-6.jpg)
![Figure 7 Vascularized tumor-on-chip (TOC) systems. (a) A gelatin and hyaluronic acid (HA) construct, built in a PDMS device, traversed by an endothelialized microchannel. Taken from reference [54]; (b) TOC devised by Ozkan et al. [55]. (i) Schematic representation of a breast tumor microenvironment connected to a healthy liver niche. (ii) Close-up view of the TOC system. Confocal images show GFP-breast cancer cells (green) and particles circulating inside the vascular channel (red) and FITC-anti-albumin immunostained healthy liver cells (green) and particles circulating inside the vascular channel (red). Scale bar: 500 µm. (iii) CFD simulation showing the cross-sectional shear stress profiles in tumor and healthy vessels. Taken from reference [55]; (c) TOC by Shirure et al. [56]. (i) Schematic representation of the device, and (ii) confocal slice of the microvascular network (green) fabricated within the TOC central chamber and perfused with fluorescently labeled dextran (orange). Scale bar: 50 µm. Taken from reference [56]; (d) Bottom-up engineering of vascularized tumor models proposed in Agarwal et al. [57]. (i) Schematic representation of the strategy. (ii) Comparison of the effect of docetaxel, expressed as IC50, for three different microtumor models: 2D (black), a-vascular 3D (blue) and vascularized 3D (red) models; (*) indicate statistically significant difference of p < 0.05 when 3D vascularized models are compared to 2D culture model, and (#) significant differences of p < 0.05 when 3D vascularized models are compared with 2D and 3D avascular culture models. Taken from reference [57]. (e) Vascularized tumor-on-chip developed by Sobrino et al. [58]. (i) Scheme of the microfluidic device: a PDMS microfluidic chip composed of an array of three tissue chambers, each connected to two straight channels mimicking an arteriole (line of higher pressure) and the venule (line of lower pressure). Channels were also connected to the medium inlets and outlets. A hydrostatic pressure differential of 10 mm H2O was established to enable flow across the microfluidic channel, while a pressure gradient of 5 mm H2O was set across the tissue chambers to favor transport across the hydrogel. (ii) A human-endothelial cell vasculature net was fabricated within diamond-shaped tissue chambers containing EC-like matrix. Remarkably, the development of vasculature in these tissue chambers occurred spontaneously by self-assembly of EC cells initially seeded within the channels and the tissue chamber at day zero. Endothelial cells were continuously transduced with mCherry for easy visualization of the network (iii) Experiments of continuous perfusion of Dextran X show that the vascular network is practically leak-free after several days. (iv) Growth of tumors, fabricated by a spheroid formation method assisted by thrombin, seeded within the vasculature network models after 6, 8, 10, and 12 days of culture at continuous perfusion. (v) Different drugs were tested in this tumor-on-chip system; (vi and vii) the model correctly discriminates between drugs that target the tumor-vasculature formation capabilities and those that target the tumor. Scale bars: 50 µm. Taken from reference [58].](https://figures.cochat.ai/paper-figures/c1fbb9d2d8a445028c0bcc79d8928c86/the-tumor-on-chip-recent-advances-in-the-development-of-microfluidic-systems-to-figure-7.jpg)
![Figure 8 Application scenarios for tumor-on-chip systems. (a) Fundamental studies [30,31,33,35,36,41,43,44,45,48,50,51,53,54,55,56,60,62,64,65,66,67,68,70,71,72,73,80,85,105,186,187,188,189,190,191,192,193]; (b) Pharmacological screening and testing [21,22,23,27,28,29,32,43,47,50,55,56,57,58,59,63,64,165,177,194]; and (c) personalized/precision medicine strategies [24,37,42,56,69,104,195,196,197,198].](https://figures.cochat.ai/paper-figures/311ce3dde0064969ab8ec026c7090291/the-tumor-on-chip-recent-advances-in-the-development-of-microfluidic-systems-to-figure-8.jpg)
Verification
Claims the paper makes
103 Valid · 4 Not valid · 30 Not checked · 12 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“For example, when Pbase was higher than Ptip, an invasive phenotype was favored”
§ The Tumor-on-Chip: Recent Advances in the Development of Microfluidic Systems to Recapitulate the Physiology of Solid Tumors > 5. Tumor-on-Chip Examples > 5.2. Spheroids in a Hydrogel Matrix
What the sources say
- Disputedcites [30] Tien, 2016, Interstitial fluid pressure regulates collective invasion in engineered human breast tumors via Snail, vimentin, and Transition to invasion, Integr. Biol. sourceExperimental — accuracy not yet measured
The Results section reports the opposite: when Pbase>Ptip, none of 51 aggregates developed invasions. Invasion was promoted when Pbase<Ptip, with 50% of aggregates developing invasions. Page numbers were not provided in the supplied passages. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“The penetration of NPs into the tissue was mainly influenced by their diameter (Figure 4a-iv–vi) and NP transport was predominantly dispersion-limited.”
§ The Tumor-on-Chip: Recent Advances in the Development of Microfluidic Systems to Recapitulate the Physiology of Solid Tumors > 5. Tumor-on-Chip Examples > 5.2. Spheroids in a Hydrogel Matrix
What the sources say
- Disputedcites [27] Albanese, 2013, Tumour-on-a-chip provides an optical window into nanoparticle tissue transport, Nat. Commun. sourceExperimental — accuracy not yet measured
The Results section (“Effect of flow rate on tissue accumulation”) says nanoparticles diffuse into spheroid tissue after accumulating at its surface; increased flow did not increase penetration depth. The claim says transport was predominantly dispersion-limited, whereas the paper describes diffusion as the mechanism of penetration. Its separate finding that diameter limits penetration is supported by the Results (“Effect of nanoparticle size on tissue accumulation”). (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Indeed, the 3D static and microfluidic models demonstrated coordinated cell-cell and cell-matrix interactions that were not detectable in the 2D static model.”
§ The Tumor-on-Chip: Recent Advances in the Development of Microfluidic Systems to Recapitulate the Physiology of Solid Tumors > 5. Tumor-on-Chip Examples > 5.4. Spheroids Surrounded by “Healthy” Tissues In some instances, tumor spheroids have been embedded in hydrogels containing normal (i.e., non-cancerous cells) within microfluidic chambers. For example, Aung et al. [50] developed a tumorous microtissue encapsulated by an endothelial barrier composed of HUVECs. The authors mixed breast cancer spheroids (MCF-7) into a suspension of HUVECs (~50 spheroids into 5 mL of a HUVEC suspension containing 0.4 × 105 cells/mL). This mix was centrifuged, and the pellet was suspended in 100 µL of 10% gelatin methacryloyl (GelMA); this new mixture was then loaded into thin microfluidic devices. Using a microscope, the authors located areas where cancer spheroids were surrounded by HUVECs and photocrosslinked these locations, flushing out the rest of the non-crosslinked hydrogel. This operation resulted in a hydrogel micro-cosmos containing spheroids surrounded by HUVEC cells. Over time, the HUVECs chemotactically migrated from the bulk of the hydrogel towards its perimeter and spontaneously developed an endothelial barrier around the GelMA construct (Figure 6a-i–iii). As a result, starting from homogeneity, the HUVEC density varied in different areas within the constructs over time (Figure 6a-iv). The size of the tumor spheroids, as determined by their projected area, also increased over time (Figure 6a-v). Thus, this tumor-on-chip produces tumor spheroids within a semisynthetic extracellular matrix embedded in a cell-monolayer endothelial barrier conformed by tight cell-cell E-cadherin junctions and encompassing the entire length of the GelMA hydrogel. This simple and smart platform was also used to evaluate the effect of DOX (Figure 6a-vi,vii). After 5 days of cultivation, they administered different doses of DOX (1, 10 and 100 µg/mL) for 3 days. Figure 6a-vi shows bright-field images of the HUVEC-MCF7 constructs before (top row) and 3 days after (bottom row) DOX treatment. Red arrows indicate the endothelial barrier. At concentrations of 10 and 100 μg/mL, DOX destroyed the endothelial barrier, decreased the size of spheroids, and caused a darkening of the MCF7 spheroids (Figure 6a-vii). Jeong et al. developed a tumor-on-chip to investigate the 3D interplay between cancer cells and fibroblasts (Figure 6b) [51]. This tumor-on-chip system consisted of four units; each unit comprised seven channels, each one 1000 μm wide and 190 μm deep (Figure 6b-i–iv). Channels 2, 6, and 4 were designated for non-cancer or cancer cell culture, and channels 1, 3, 5, and 7 were used for medium filling (Figure 6b-iii). The device was designed for intermittent feeding and the cell culture medium was changed every day. A collagen I solution (2 mg/mL) was mixed with the cells before being loaded into the device channels. Mono- and co-cultures of HT29 cancer cells and normal fibroblasts (CCD-18Co) were performed (Figure 6b-v) and, in some experiments, naïve collagen I (without cells) was loaded in the different channels of the device. A crosstalk between the cancer cells and fibroblasts was observed. After 5 days, the HT-29 cells formed viable spheroids and their growth was stimulated by co-culture with fibroblasts (Figure 6b-v). Increased expression of α-SMA and enhanced migration activity suggested fibroblast activation. The authors also observed changes in the expression of intracellular proteins related to angiogenesis and apoptosis. For instance, CD26, GM-CSF, SerpinE1, TIMP-1, HB-EGF, TSP-1, and GDNF were up-regulated and phospho-p53 (S15), phospho-p53 (S46), phospho-p53 (S392), pro-caspase-3, and cytochrome C were down-regulated in the tumor spheroids in co-culture. The spheroids co-cultured with fibroblasts exhibited increased expression of fibronectin, along with reduced expression of Ki-67. The effects of DOX and paclitaxel were also evaluated in this platform. Co-cultured spheroids also exhibited lower levels of DOX uptake and reduced sensitivity to paclitaxel (Figure 6b-vii). This 3D co-culture platform enabled the study of tumor microenvironment factors related to the epithelial-mesenchymal transition process, fibroblast activation, and drug resistance. Aref et al. conducted experiments in a commercial DAX-1 microfluidic system (Aim Biotech) in which patient-derived spheroids (PDOSTS) were cultured in contact with immune system cells to recreate the tumor immune microenvironment and screen the response of tumors to immunotherapy (therapies based on antibodies) [48]. Tumor biopsies from patients were mechanically and enzymatically dissociated to yield spheroids, cell agglomerates, and single cells (Figure 6c-i). The spheroids were separated for culture in the DAX-1 microfluidic device (Figure 6b). The DAX-1 chip was composed of three microfluidic chambers—a central gel channel surrounded by two channels for media circulation (Figure 6c-ii). The PDOSTS spheroids (40–100 μm in diameter) were embedded in collagen type I hydrogels in the central chamber and cultured. In the side channels, medium with or without monoclonal antibodies was circulated. The authors demonstrated the presence of autologous tumor-infiltrating immune cells (CD8-T) (Figure 6c-iii). Treatment with an anti-PD-1 antibody showed cancer cell death mediated by CD8 T-cells. Analysis of cytokines (Figure 6c-iv,v) revealed a natural evolution of cytokine and growth factor secretion over time (e.g., IL-8 VEGF, IL-12, CCL4). This study demonstrated that patient-derived tumor spheroids retain lymphoid and myeloid subsets of immune cells and that those cell populations could be further cultured in microfluidic chips. Bruce et al. studied acute lymphoblastic leukemia (ALL) in a 3D microfluidic system (Figure 6d) [49]. The device consisted of four perfusion microchannels. Chip dimensions were set considering the nutrient diffusion limits (i.e., relevant diffusional length scales) and aimed to recreate the interplay between the different cell types involved in ALL (Figure 6d-i,ii). Cell loading and culture medium feeding was performed through two ports (“cell in” and “media in”) placed at the inlet side of the device. SUP-B15 leukemic cells were cultured in the presence or absence of human bone marrow stromal cells (BMSCs) and human osteoblasts (HOBs). Cells were suspended in medium with 88% collagen type I—a concentration that is consistent with the stiffness of bone marrow (< 300 Pa). After collagen I gelation, culture medium was fed through the inlet and into the microchannels. Velocity profiles within the microchannels, set to be similar to that in the interstitial space of the bone marrow, were maintained at 0.27 ± 0.18 μm/s. Cell culture was performed in 2D static, 3D static, and 3D microfluidic models (Figure 6d-iv–vi), and significant differences in cell morphology and expression were found. The authors used this microfluidic platform to evaluate cell-cell and cell-matrix interplay in a controlled microenvironment that recapitulated physiological ranges of critical dynamical variables. Indeed, the 3D static and microfluidic models demonstrated coordinated cell-cell and cell-matrix interactions that were not detectable in the 2D static model. The 3D platform proved to be a more accurate bone marrow niche model, where different cells in culture (leukemic cells, human bone marrow stromal cells, and human osteoblasts) could interact in a dynamic fashion. In addition, chemoresistance studies were carried out by exposing 2D and 3D cultures to cytarabine (Ara-C), and the bone marrow microenvironment was found to have a protective role in cancer cell survival during treatment. Moreover, a lower chemotherapeutic sensitivity of leukemic cells was observed in the 3D tri-culture models than in the 2D models (Figure 6d-vii,viii). The 3D microfluidic model developed in this work is a suitable in vitro option for the study of tumor cell biology in the bone marrow niche (i.e., the space where the leukemic disease is initiated) and the site of metastatic malignancies characterized by high anticancer drug resistance.
What the sources say
- Disputedcites [49] Bruce, A., Evans, R., Mezan, R., Shi, L., Moses, B.S., Martin, K.H., Gibson, L.F., and Yang, Y. (2015). Three-Dimensional Microfluidic Tri-Culture Model of the Bone Marrow Microenvironment for Study of Acute Lymphoblastic Leukemia. PLoS ONE, 10. sourceExperimental — accuracy not yet measured
In Results and Discussion, “Cell-Cell Interactions” (page not supplied), the paper says direct cell-cell interactions were visible in the 2-D static model, contrary to the claim that they were not detectable there. It also says the 3-D static model lacked interaction without dynamic stresses. The paper favors the 3-D microfluidic model as a more authentic niche, but not the claimed contrast across all three models. (LLM, conf=0.87)
Checked by a reasoning model — may be wrong.
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition to their remarkable internal heterogeneity, the tumor stromal tissues (i.e., the tissues surrounding the tumor), act as a dynamic source (and reservoir) of various cytokines and growth factors that influence tumor progression and pharmacological responses [19].”
§ The Tumor-on-Chip: Recent Advances in the Development of Microfluidic Systems to Recapitulate the Physiology of Solid Tumors > 2. The Tumor Niche
What the sources say
- Supportedcites [19] Han, 2016, Recapitulation of complex transport and action of drugs at the tumor microenvironment using tumor-microenvironment-on-chip, Cancer Lett. source
The Introduction describes stromal tissue as a repository for growth factors and cytokines that influence tumor growth and drug response. Section 2 also describes stromal-associated cells producing cytokines and links the resulting chemical environment to tumor progression and therapeutic resistance. Page numbers are not provided in our copy. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Recently, organ-on-chip systems—microphysiological systems that combine the use of microfluidics, tissue engineering, and microfabrication tools—have shown promise sustaining functional microtissues for relatively extended timeframes [9,10,11,12].”
§ The Tumor-on-Chip: Recent Advances in the Development of Microfluidic Systems to Recapitulate the Physiology of Solid Tumors > 1. Introduction
What the sources say
- Not checked — no full text of the sourcecites [9] Zheng, 2016, Organ-on-a-Chip Systems: Microengineering to Biomimic Living Systems, Small source
- Partly supportedcites [10] Esch, 2015, Organs-on-chips at the frontiers of drug discovery, Nat. Rev. Drug Discov. sourceExperimental — accuracy not yet measured
The ‘Comparison with conventional models’ section says organs-on-chips can reconstitute organ-level physiological functions, supporting the functional-microtissue part of the claim. But the passages do not establish that this function is sustained for relatively extended periods; ‘Current challenges and limitations’ instead describes long-term culture as a major challenge. Page numbers are not available in our copy. (LLM, conf=0.84)
- Supportedcites [11] Trujillo-de Santiago, G., Lobo-Zegers, M.J., Montes-Fonseca, S.L., Zhang, Y.S., and Alvarez, M.M. (2018). Gut-microbiota-on-a-chip: An enabling field for physiological research. Microphysiol. Syst., 2. source
The “Microbiota-related studies in gut-on-chip systems” section (page unavailable) describes Caco-2 cells cultured for one week in a gut-on-chip model and reports tests of epithelial barrier integrity. It also reports that a Caco-2 monolayer remained viable during 48 hours of exposure to bacterial biofilm products, supporting the hedged claim that such systems show promise for sustaining functional tissue models over extended periods. (LLM, conf=0.85)
- Not checked — no full text of the sourcecites [12] Zhang, 2017, Organ-on-a-chip devices advance to market, Lab Chip source
plainstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
100 more claims · 74 with their cited sources checked
Create a free account to see all 149 claims and to verify the 11 references still open.
- It may state two separate claims as one. 33
- Probably not a substantial claim. 10
- The quote only partly states this claim. 2
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“These systems enable continuous delivery of oxygen, nutrients, and therapeutic agents while introducing shear stress and directional mass transport, thereby allowing the investigation of flow-regulated processes within a tumor-relevant architecture [224,225,226,227,228].”
From Modeling Tumor Microenvironment Complexity In Vitro: Spheroids as Physiologically Relevant Tumor Models and Strategies for Their Analysis (2025) · cites this paper as [225]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The Tumor-on-Chip: Recent Advances in the Development of Microfluidic Systems to Recapitulate the Physiology of Solid Tumors > 5. Tumor-on-Chip Examples > 5.3. Non-Spheroid Models where 3D Cancer Tissues are in Contact with Non-Cancerous Tissues
“The HMFs and MCF10-DCIS cells established a crosstalk at the interface between the cancerous and normal microtissue sections.”
§ The Tumor-on-Chip: Recent Advances in the Development of Microfluidic Systems to Recapitulate the Physiology of Solid Tumors > 5. Tumor-on-Chip Examples > 5.3. Non-Spheroid Models where 3D Cancer Tissues are in Contact with Non-Cancerous Tissues
“The change in shape of MCF710-DCIS cells, and their ability to remodel the matrix, suggested the onset of a DCIS to IDS transition.”
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109 · cited 2×
“5 million will die from this disease, according to GLOBOCAN 2018 estimates [1].”
BackgroundStem cells, cancer, and cancer stem cells
Reya, T., Morrison, S. J., Clarke, M. F., & Weissman, I. L. (2001) · Nature · doi:10.1038/35102167 · Cited by 9,738 · cited 1×
“In the end, cancer is a genetic disorder [88,89].”
BackgroundAngiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070 · cited 2×
“Therefore, vascularization is another relevant aspect to consider when engineering a tumor local microenvironment [180,181].”
BackgroundVogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863 · cited 1×
“The nature of these mutations differs for each cancer [90] and in each individual [90–92].”
BackgroundMacrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm
Biswas, S. K., & Mantovani, A. (2010) · Nature Immunology · doi:10.1038/ni.1937 · Cited by 3,840
Synthesis, properties, and biomedical applications of gelatin methacryloyl (GelMA) hydrogels
Yue, K., Trujillo-de Santiago, G., Alvarez, M. M., Tamayol, A., Annabi, N., & Khademhosseini, A. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.08.045 · Cited by 3,146 · cited 1×
“Several techniques also involve the use of semi-synthetic polymers, such as gelatin methacryloyl (GelMA) [166] based hydrogels [135,167], or self-assembling peptides, such as RADA16-I, Q11, and bQ13, that can form gels under specific conditions (e.”
BackgroundHoadley, K. A., Yau, C., Hinoue, T., Wolf, D. M., Lazar, A. J., Drill, E., Shen, R., Taylor, A. M., Cherniack, A. D., Thorsson, V., et al. (2018) · Cell · doi:10.1016/j.cell.2018.03.022 · Cited by 2,546
Ferlay, J., Colombet, M., Soerjomataram, I., Dyba, T., Randi, G., Bettio, M., Gavin, A., Visser, O., & Bray, F. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.07.005 · Cited by 2,478
The causes and consequences of genetic heterogeneity in cancer evolution
Burrell, R. A., McGranahan, N., Bartek, J., & Swanton, C. (2013) · Nature · doi:10.1038/nature12625 · Cited by 2,262
The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy
Muz, B., de la Puente, P., Azab, F., & Azab, A. K. (2015) · Hypoxia · doi:10.2147/hp.s93413 · Cited by 2,066 · cited 1×
“For instance, recently published literature discusses the role of the size of a tumor (and the associated hypoxia levels) on its aggressiveness [81–85] and on the efficacy of drug delivery to it [84,86,87].”
BackgroundSpheroid-based drug screen: Considerations and practical approach
Friedrich, J., Seidel, C., Ebner, R., & Kunz-Schughart, L. A. (2009) · Nature Protocols · doi:10.1038/nprot.2008.226 · Cited by 1,742 · cited 2×
“Adhesion can be prevented by coating the culture surface with agar [153], agarose [120,130,152,154], poly (2-hydroxyethyl methacrylate) (polyHEMA) [125], or tri-block co-polymers, such as Pluronic (F108) [26].”
BackgroundVleminckx, K., Vakaet, L., Mareel, M., Fiers, W., & Van Roy, F. (1991) · Cell · doi:10.1016/0092-8674(91)90143-m · Cited by 1,656 · cited 1×
“For example, the role of E-cadherin as a suppressor of cancer invasiveness has been widely cited [75,76].”
BackgroundHypoxia and the extracellular matrix: drivers of tumour metastasis
Gilkes, D. M., Semenza, G. L., & Wirtz, D. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3726 · Cited by 1,520
Patient-derived tumour xenografts as models for oncology drug development
Tentler, J. J., Tan, A. C., Weekes, C. D., Jimeno, A., Leong, S., Pitts, T. M., Arcaroli, J. J., Messersmith, W. A., & Eckhardt, S. G. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.61 · Cited by 1,277 · cited 1×
“By contrast, animal models are research platforms that satisfy the 3D requirement [94,95] and provide an in vivo setting to study tumor growth, behavior, and treatment.”
BackgroundOrgans-on-chips at the frontiers of drug discovery
Esch, E. W., Bahinski, A., & Huh, D. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4539 · Cited by 1,185
Genin, M., Clement, F., Fattaccioli, A., Raes, M., & Michiels, C. (2015) · BMC Cancer · doi:10.1186/s12885-015-1546-9 · Cited by 1,090
Lost in translation: animal models and clinical trials in cancer treatment.
(2014) · Europe PMC (PubMed Central) · Cited by 1,033
Cancer incidence and mortality in China, 2014
Chen, W., National Office for Cancer Prevention and Control, N. C. C. H., Sun, K., Zheng, R., Zeng, H., Zhang, S., Xia, C., Yang, Z., Li, H., Zou, X., et al. (2018) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2018.01.01 · Cited by 1,007
Kelm, J. M., Timmins, N. E., Brown, C. J., Fussenegger, M., & Nielsen, L. K. (2003) · Biotechnology and Bioengineering · doi:10.1002/bit.10655 · Cited by 934
3D tumor spheroids: an overview on the tools and techniques used for their analysis
Costa, E. C., Moreira, A. F., de Melo-Diogo, D., Gaspar, V. M., Carvalho, M. P., & Correia, I. J. (2016) · Biotechnology Advances · doi:10.1016/j.biotechadv.2016.11.002 · Cited by 929 · cited 2×
“Despite their simplicity, they hold great promise for the recapitulation of solid tumors in many relevant aspects [22,29,116,117].”
BackgroundThree-dimensional culture systems in cancer research: Focus on tumor spheroid model
Nath, S., & Devi, G. R. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.03.013 · Cited by 919 · cited 3×
“Cancer spheroids are arguably the simplest in vitro 3D tumor models [114,115].”
BackgroundModelling cancer in microfluidic human organs-on-chips
Sontheimer-Phelps, A., Hassell, B. A., & Ingber, D. E. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-018-0104-6 · Cited by 906
Three-dimensional microfluidic model for tumor cell intravasation and endothelial barrier function
Zervantonakis, I. K., Hughes-Alford, S. K., Charest, J. L., Condeelis, J. S., Gertler, F. B., & Kamm, R. D. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1210182109 · Cited by 872 · cited 2×
“[30,56,62,65-68,70-72,85,189-192] [22,23,29,32,43,50,5559,63,64,165,177,194] [21,27,28,47,64]”
Engineering of functional, perfusable 3D microvascular networks on a chip
Kim, S., Lee, H., Chung, M., & Jeon, N. L. (2013) · Lab on a Chip · doi:10.1039/c3lc41320a · Cited by 872 · cited 1×
“Indeed, vascular transport is particularly required for tissues with diffusional distances greater than 200 μm [8,182,183], and tumors are not an exception.”
BackgroundMaschmeyer, I., Lorenz, A. K., Schimek, K., Hasenberg, T., Ramme, A. P., Hübner, J., Lindner, M., Drewell, C., Bauer, S., Thomas, A., et al. (2015) · Lab on a Chip · doi:10.1039/c5lc00392j · Cited by 861
In Vitro Tumor Models: Advantages, Disadvantages, Variables, and Selecting the Right Platform
Katt, M. E., Placone, A. L., Wong, A. D., Xu, Z. S., & Searson, P. C. (2016) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2016.00012 · Cited by 754 · cited 1×
“, they are not based on microfluidics) [102], but they do provide a valuable alternative to animal models and have enabled important advances in cancer research in the last two decades [5,103].”
BackgroundHuman 3D vascularized organotypic microfluidic assays to study breast cancer cell extravasation
Jeon, J. S., Bersini, S., Gilardi, M., Dubini, G., Charest, J. L., Moretti, M., & Kamm, R. D. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1417115112 · Cited by 723 · cited 2×
“[30,56,62,65-68,70-72,85,189-192] [22,23,29,32,43,50,5559,63,64,165,177,194] [21,27,28,47,64]”
Nunes, A. S., Barros, A. S., Costa, E. C., Moreira, A. F., & Correia, I. J. (2019) · Biotechnology and Bioengineering · doi:10.1002/bit.26845 · Cited by 721 · cited 3×
“The end result is a reduction in the consumption of reagents, a higher density of cells, a higher cell to fluid ratio, and real-time control of delivery of nutrients and reagents [20,124,145,173,174].”
Background3D printed microfluidics for biological applications
Ho, C. M. B., Ng, S. H., Li, K. H. H., & Yoon, Y.-J. (2015) · Lab on a Chip · doi:10.1039/c5lc00685f · Cited by 704 · cited 1×
“The advent of high-resolution 3D-printing technologies will enable the easier fabrication of more complex and functional organ-on-chip devices [202,203].”
BackgroundMolecular landmarks of tumor hypoxia across cancer types
Bhandari, V., Hoey, C., Liu, L. Y., Lalonde, E., Ray, J., Livingstone, J., Lesurf, R., Shiah, Y.-J., Vujcic, T., Huang, X., et al. (2019) · Nature Genetics · doi:10.1038/s41588-018-0318-2 · Cited by 678
The role of stroma in pancreatic cancer: Diagnostic and therapeutic implications
Erkan, M., Hausmann, S., Michalski, C. W., Fingerle, A. A., Dobritz, M., Kleeff, J., & Friess, H. (2012) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2012.115 · Cited by 662 · cited 2×
“Besides, animal models typically fail to provide a precise recapitulation of human physiology [74,100,101].”
BackgroundM2 Macrophage-Derived Exosomes Promote Cell Migration and Invasion in Colon Cancer
Lan, J., Sun, L., Xu, F., Liu, L., Hu, F., Song, D., Hou, Z., Wu, W., Luo, X., Wang, J., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-0014 · Cited by 643
A liver-on-a-chip platform with bioprinted hepatic spheroids
Bhise, N. S., Manoharan, V., Massa, S., Tamayol, A., Ghaderi, M., Miscuglio, M., Lang, Q., Shrike Zhang, Y., Shin, S. R., Calzone, G., et al. (2016) · Biofabrication · doi:10.1088/1758-5090/8/1/014101 · Cited by 615 · cited 1×
“Several techniques also involve the use of semi-synthetic polymers, such as gelatin methacryloyl (GelMA) [166] based hydrogels [135,167], or self-assembling peptides, such as RADA16-I, Q11, and bQ13, that can form gels under specific conditions (e.”
BackgroundSelf-citationCancer-associated fibroblasts promote directional cancer cell migration by aligning fibronectin
Erdogan, B., Ao, M., White, L. M., Means, A. L., Brewer, B. M., Yang, L., Washington, M. K., Shi, C., Franco, O. E., Weaver, A. M., et al. (2017) · Journal of Cell Biology · doi:10.1083/jcb.201704053 · Cited by 552 · cited 2×
“, cancer cells, various stromal cells, such as cancer-associated fibroblasts [73], various types of immune cells, and vascular cells) and rich extracellular matrix components (i.”
BackgroundThree-dimensional printing of Hela cells for cervical tumor model in vitro
Zhao, Y., Yao, R., Ouyang, L., Ding, H., Zhang, T., Zhang, K., Cheng, S., & Sun, W. (2014) · Biofabrication · doi:10.1088/1758-5082/6/3/035001 · Cited by 534
A microfluidic 3D in vitro model for specificity of breast cancer metastasis to bone
Bersini, S., Jeon, J. S., Dubini, G., Arrigoni, C., Chung, S., Charest, J. L., Moretti, M., & Kamm, R. D. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2013.11.050 · Cited by 534 · cited 3×
“Pioneering examples of human-on-chip systems to model tumor metastasis have been recently published [67,192,225].”
BackgroundInterstitial flow influences direction of tumor cell migration through competing mechanisms
Polacheck, W. J., Charest, J. L., & Kamm, R. D. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1103581108 · Cited by 509 · cited 1×
“Recent reviews have described the current use of microfluidics to investigate different aspects of the physiology of cancer, including (a) cell migration in the tumor microenvironment [105,109], metastasis events [110], anticancer drug screening and therapy response predictions [111], or the study of the transport of…”
BackgroundAdvances in multicellular spheroids formation
Cui, X., Hartanto, Y., & Zhang, H. (2017) · Journal of The Royal Society Interface · doi:10.1098/rsif.2016.0877 · Cited by 508
Hassell, B. A., Goyal, G., Lee, E., Sontheimer-Phelps, A., Levy, O., Chen, C. S., & Ingber, D. E. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.09.043 · Cited by 467
Organ-on-a-chip devices advance to market
Zhang, B., & Radisic, M. (2017) · Lab on a Chip · doi:10.1039/c6lc01554a · Cited by 437 · cited 1×
“For example, the fabrication of microfluidic devices is still a task that requires skill and experience [12,201].”
BackgroundOrgan/body-on-a-chip based on microfluidic technology for drug discovery
Kimura, H., Sakai, Y., & Fujii, T. (2018) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2017.11.003 · Cited by 435 · cited 1×
“Human-on-chips systems that recapitulate not only the tumor niche but also one or more possible target metastasis organs connected throughout a vascular/fluidic network—will be a highly valuable tool for proper modeling of metastasis [99,223,224].”
BackgroundRapid Continuous Multimaterial Extrusion Bioprinting
Liu, W., Zhang, Y. S., Heinrich, M. A., De Ferrari, F., Jang, H. L., Bakht, S. M., Alvarez, M. M., Yang, J., Li, Y., Trujillo‐de Santiago, G., et al. (2017) · Advanced Materials · doi:10.1002/adma.201604630 · Cited by 424
Self-citationLimits to Personalized Cancer Medicine
Tannock, I. F., & Hickman, J. A. (2016) · New England Journal of Medicine · doi:10.1056/nejmsb1607705 · Cited by 415
The production of 3D tumor spheroids for cancer drug discovery
Sant, S., & Johnston, P. A. (2017) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2017.03.002 · Cited by 404 · cited 7×
“Modified from Sant and Johnston 2017 [126]; (b) Fabrication of spheroids by the following scaffold-free methods: (i) hanging drop [122,127–129], (ii) liquid-overlay method [130–136], and (iii) force-driven method [129,132,137–141]; (c) Fabrication of spheroids by the following scaffold-based…”
BackgroundMethodInfluentialIn Vitro Perfused Human Capillary Networks
Moya, M. L., Hsu, Y.-H., Lee, A. P., Hughes, C. C. W., & George, S. C. (2013) · Tissue Engineering Part C: Methods · doi:10.1089/ten.tec.2012.0430 · Cited by 387 · cited 1×
“Indeed, vascular transport is particularly required for tissues with diffusional distances greater than 200 μm [8,182,183], and tumors are not an exception.”
BackgroundReconfigurable microfluidic hanging drop network for multi-tissue interaction and analysis
Frey, O., Misun, P. M., Fluri, D. A., Hengstler, J. G., & Hierlemann, A. (2014) · Nature Communications · doi:10.1038/ncomms5250 · Cited by 387 · cited 2×
“Although other methods have been proposed [150,151,171,172], the generation of spheroids by microfluidic techniques is done mainly by approaches based on micro-molding and micro-droplets.”
Method3D microtumors in vitro supported by perfused vascular networks
Sobrino, A., Phan, D. T. T., Datta, R., Wang, X., Hachey, S. J., Romero-López, M., Gratton, E., Lee, A. P., George, S. C., & Hughes, C. C. W. (2016) · Scientific Reports · doi:10.1038/srep31589 · Cited by 387 · cited 2×
“[48-53] [54-72] Spheroids in microfluidic chambers Spheroids in a hydrogel matrix”
BackgroundChen, M. B., Whisler, J. A., Fröse, J., Yu, C., Shin, Y., & Kamm, R. D. (2017) · Nature Protocols · doi:10.1038/nprot.2017.018 · Cited by 385
Lee, H., & Cho, D.-W. (2016) · Lab on a Chip · doi:10.1039/c6lc00450d · Cited by 363 · cited 1×
“Among all emerging biofabrication techniques, we would argue that bioprinting [205] holds the highest promise to make a decisive contribution to improve the engineering of tumors for cancer research [206].”
BackgroundBioprinting for cancer research
Knowlton, S., Onal, S., Yu, C. H., Zhao, J. J., & Tasoglu, S. (2015) · Trends in Biotechnology · doi:10.1016/j.tibtech.2015.06.007 · Cited by 361
Hydrogel microenvironments for cancer spheroid growth and drug screening
Li, Y., & Kumacheva, E. (2018) · Science Advances · doi:10.1126/sciadv.aas8998 · Cited by 351
Organ-on-a chip systems: microengineering to biomimic living systems
Zheng, F., Fu, F., Cheng, Y., Wang, C., Zhao, Y., & Gu, Z. (2016) · Small · doi:10.1002/smll.201503208 · Cited by 338
Preclinical mouse solid tumour models: status quo, challenges and perspectives
Gengenbacher, N., Singhal, M., & Augustin, H. G. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.92 · Cited by 332 · cited 1×
“By contrast, animal models are research platforms that satisfy the 3D requirement [94,95] and provide an in vivo setting to study tumor growth, behavior, and treatment.”
BackgroundTumour-on-a-chip provides an optical window into nanoparticle tissue transport
Albanese, A., Lam, A. K., Sykes, E. A., Rocheleau, J. V., & Chan, W. C. W. (2013) · Nature Communications · doi:10.1038/ncomms3718 · Cited by 330 · cited 11×
“A mix of Matrigel and collagen I (1:1) was used as the loading matrix.”
BackgroundMethodInfluentialEngineering cancer microenvironments for in vitro 3-D tumor models
Asghar, W., El Assal, R., Shafiee, H., Pitteri, S., Paulmurugan, R., & Demirci, U. (2015) · Materials Today · doi:10.1016/j.mattod.2015.05.002 · Cited by 316
Shirure, V. S., Bi, Y., Curtis, M. B., Lezia, A., Goedegebuure, M. M., Goedegebuure, S. P., Aft, R., Fields, R. C., & George, S. C. (2018) · Lab on a Chip · doi:10.1039/c8lc00596f · Cited by 316 · cited 6×
“Several recent contributions demonstrate the use of CFD simulations to study the transport of materials near a tumor in tumor-on-chip systems [26,56] or in vivo [220].”
BackgroundInfluentialMechanisms of tumor cell extravasation in an in vitro microvascular network platform
Chen, M. B., Whisler, J. A., Jeon, J. S., & Kamm, R. D. (2013) · Integrative Biology · doi:10.1039/c3ib40149a · Cited by 308 · cited 1×
“[48-53] [54-72] Spheroids in microfluidic chambers Spheroids in a hydrogel matrix”
3D Bioprinting a Cell-Laden Bone Matrix for Breast Cancer Metastasis Study
Zhou, X., Zhu, W., Nowicki, M., Miao, S., Cui, H., Holmes, B., Glazer, R. I., & Zhang, L. G. (2016) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6b10673 · Cited by 307
Dynamic analysis of hepatoma spheroid formation: roles of E-cadherin and β1-integrin
Lin, R.-Z., Chou, L.-F., Chien, C.-C. M., & Chang, H.-Y. (2006) · Cell and Tissue Research · doi:10.1007/s00441-005-0148-2 · Cited by 305 · cited 1×
“This formation takes place in three stages [127]: disperse cells first form loose aggregates through the binding of their ECM fibers (highly loaded with RGD motifs) that act as long-chain linkers of cell membrane integrins; second, direct cell-cell contact upregulates the expression of E-cadherin, which accumulates in…”
Background3D bioprinted glioma stem cells for brain tumor model and applications of drug susceptibility
Dai, X., Ma, C., Lan, Q., & Xu, T. (2016) · Biofabrication · doi:10.1088/1758-5090/8/4/045005 · Cited by 301
Xu, Z., Gao, Y., Hao, Y., Li, E., Wang, Y., Zhang, J., Wang, W., Gao, Z., & Wang, Q. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.02.045 · Cited by 295
Translational value of mouse models in oncology drug development
Gould, S. E., Junttila, M. R., & de Sauvage, F. J. (2015) · Nature Medicine · doi:10.1038/nm.3853 · Cited by 293 · cited 1×
“However, animal models have their own complications [7,17,96] because they are time-, resource-, and expertise-intensive, and animal use is increasingly being questioned by different public entities for ethical/humanitarian concerns [97–99].”
BackgroundJeong, S.-Y., Lee, J.-H., Shin, Y., Chung, S., & Kuh, H.-J. (2016) · PLOS ONE · doi:10.1371/journal.pone.0159013 · Cited by 287 · cited 5×
“Taken from reference [51]; (c) TOC developed by Aref et al.”
BackgroundMethodInfluentialLazzari, G., Nicolas, V., Matsusaki, M., Akashi, M., Couvreur, P., & Mura, S. (2018) · Acta Biomaterialia · doi:10.1016/j.actbio.2018.08.008 · Cited by 271 · cited 1×
“Unlike monolayer cell cultures, these single-cell type or multi-cell type cellular bodies [118,119] resemble the 3D architecture of actual solid tumors, show an organized cellular architecture, and exhibit realistic cell-cell and cell-extra cellular matrix (ECM) interactions [115,120] as compared to 2D culture systems.”
BackgroundPersonalised organs-on-chips: functional testing for precision medicine
van den Berg, A., Mummery, C. L., Passier, R., & van der Meer, A. D. (2019) · Lab on a Chip · doi:10.1039/c8lc00827b · Cited by 270 · cited 2×
“In the very near future, tumor-on-chip systems promise to be powerful enablers of anticancer personalized/precision medicine [18].”
BackgroundMoshksayan, K., Kashaninejad, N., Warkiani, M. E., Lock, J. G., Moghadas, H., Firoozabadi, B., Saidi, M. S., & Nguyen, N.-T. (2018) · Sensors and Actuators B: Chemical · doi:10.1016/j.snb.2018.01.223 · Cited by 267 · cited 1×
“Microfluidic approaches [176] hold several advantages over conventional methods for spheroid fabrication, such as higher throughput, continuous production, precise control of the pressure gradients and sheer stresses to which cells will be exposed, less reagent consumption, and uniformity of spheroid shape and size.”
BackgroundMultiscale bioprinting of vascularized models
Miri, A. K., Khalilpour, A., Cecen, B., Maharjan, S., Shin, S. R., & Khademhosseini, A. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2018.08.006 · Cited by 267 · cited 1×
“In particular, 3D bioprinting will be also a valuable asset [208,209].”
Background3D microfluidic ex vivo culture of organotypic tumor spheroids to model immune checkpoint blockade
Aref, A. R., Campisi, M., Ivanova, E., Portell, A., Larios, D., Piel, B. P., Mathur, N., Zhou, C., Coakley, R. V., Bartels, A., et al. (2018) · Lab on a Chip · doi:10.1039/c8lc00322j · Cited by 265 · cited 4×
“[48-53] [54-72] Spheroids in microfluidic chambers Spheroids in a hydrogel matrix”
BackgroundMethodInfluentialXu, Z., Li, E., Guo, Z., Yu, R., Hao, H., Xu, Y., Sun, Z., Li, X., Lyu, J., & Wang, Q. (2016) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6b08746 · Cited by 264
3D Bioprinted in vitro metastatic models via reconstruction of tumor microenvironments
Meng, F., Meyer, C. M., Joung, D., Vallera, D. A., McAlpine, M. C., & Panoskaltsis‐Mortari, A. (2019) · Advanced Materials · doi:10.1002/adma.201806899 · Cited by 262
Design of spherically structured 3D in vitro tumor models -Advances and prospects
Ferreira, L. P., Gaspar, V. M., & Mano, J. F. (2018) · Acta Biomaterialia · doi:10.1016/j.actbio.2018.05.034 · Cited by 249 · cited 2×
“Nevertheless, better 3D tumor models are still required to obtain a more faithful recapitulation of the high complexity of human tumors [103].”
BackgroundBioprinting the Cancer Microenvironment
Zhang, Y. S., Duchamp, M., Oklu, R., Ellisen, L. W., Langer, R., & Khademhosseini, A. (2016) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.6b00246 · Cited by 248 · cited 2×
“approaches [210–212] will certainly simplify the fabrication of complex tumorous tissues [206,213].”
BackgroundSelf-citationChan, H. F., Zhang, Y., Ho, Y.-P., Chiu, Y.-L., Jung, Y., & Leong, K. W. (2013) · Scientific Reports · doi:10.1038/srep03462 · Cited by 245 · cited 1×
“Recent reports have described the high-throughput and continuous fabrication of tumor spheroids of tunable size by microfluidic means [57,119,169,170].”
BackgroundSelf-citationIn vitro model of tumor cell extravasation
Jeon, J. S., Zervantonakis, I. K., Chung, S., Kamm, R. D., & Charest, J. L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056910 · Cited by 233 · cited 2×
“[30,56,62,65-68,70-72,85,189-192] [22,23,29,32,43,50,5559,63,64,165,177,194] [21,27,28,47,64]”
Skardal, A., Devarasetty, M., Forsythe, S., Atala, A., & Soker, S. (2016) · Biotechnology and Bioengineering · doi:10.1002/bit.25950 · Cited by 230
Microfluidic modelling of the tumor microenvironment for anti-cancer drug development
Shang, M., Soon, R. H., Lim, C. T., Khoo, B. L., & Han, J. (2019) · Lab on a Chip · doi:10.1039/c8lc00970h · Cited by 227
Sung, K. E., Yang, N., Pehlke, C., Keely, P. J., Eliceiri, K. W., Friedl, A., & Beebe, D. J. (2011) · Integr. Biol. · doi:10.1039/c0ib00063a · Cited by 226 · cited 7×
“developed a simple tumor-on-chip to study a key step in breast cancer progression, namely the transition of ductal carcinoma in situ (DCIS) into invasive ductal carcinoma (IDC) [33].”
BackgroundInfluentialThe Emerging Frontiers and Applications of High-Resolution 3D Printing
Mao, M., He, J., Li, X., Zhang, B., Lei, Q., Liu, Y., & Li, D. (2017) · Micromachines · doi:10.3390/mi8040113 · Cited by 224
Costa, E. C., de Melo‐Diogo, D., Moreira, A. F., Carvalho, M. P., & Correia, I. J. (2018) · Biotechnology Journal · doi:10.1002/biot.201700417 · Cited by 224 · cited 5×
“Other liquid-overlay culture methods rely on preventing adhesion of the cells to culture surfaces to favor cell-cell adhesion and the formation of aggregates [115,152].”
BackgroundInfluentialA microengineered pathophysiological model of early-stage breast cancer
Choi, Y., Hyun, E., Seo, J., Blundell, C., Kim, H. C., Lee, E., Lee, S. H., Moon, A., Moon, W. K., & Huh, D. (2015) · Lab on a Chip · doi:10.1039/c5lc00514k · Cited by 222 · cited 1×
“co-cultured breast spheroids (MCF10-DCIS), HMFs, and human mammary epithelial cells (HMT-3522; S1) embedded in a collagen type I-hydrogel to replicate the microarchitecture of DCIS in a tumor-on-chip (Figure 5c-i) [34].”
MethodOrgan-on-chip models of cancer metastasis for future personalized medicine: From chip to the patient
Caballero, D., Kaushik, S., Correlo, V. M., Oliveira, J. M., Reis, R. L., & Kundu, S. C. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.10.005 · Cited by 221 · cited 3×
“However, animal models have their own complications [7,17,96] because they are time-, resource-, and expertise-intensive, and animal use is increasingly being questioned by different public entities for ethical/humanitarian concerns [97–99].”
BackgroundOrgan-on-a-Chip for Cancer and Immune Organs Modeling
Sun, W., Luo, Z., Lee, J., Kim, H., Lee, K., Tebon, P., Feng, Y., Dokmeci, M. R., Sengupta, S., & Khademhosseini, A. (2019) · Advanced Healthcare Materials · doi:10.1002/adhm.201801363 · Cited by 221
Gelatine Methacrylamide-Based Hydrogels: An Alternative Three-Dimensional Cancer Cell Culture System
Kaemmerer, E., Melchels, F. P. W., Holzapfel, B. M., Meckel, T., Hutmacher, D. W., & Loessner, D. (2014) · Acta Biomaterialia · doi:10.1016/j.actbio.2014.02.035 · Cited by 219 · cited 2×
“Several techniques also involve the use of semi-synthetic polymers, such as gelatin methacryloyl (GelMA) [166] based hydrogels [135,167], or self-assembling peptides, such as RADA16-I, Q11, and bQ13, that can form gels under specific conditions (e.”
BackgroundPatra, B., Peng, C.-C., Liao, W.-H., Lee, C.-H., & Tung, Y.-C. (2016) · Scientific Reports · doi:10.1038/srep21061 · Cited by 215
Tumour-on-a-chip: microfluidic models of tumour morphology, growth and microenvironment
Tsai, H.-F., Trubelja, A., Shen, A. Q., & Bao, G. (2017) · Journal of The Royal Society Interface · doi:10.1098/rsif.2017.0137 · Cited by 214
Mammosphere Formation in Breast Carcinoma Cell Lines Depends upon Expression of E-cadherin
Manuel Iglesias, J., Beloqui, I., Garcia-Garcia, F., Leis, O., Vazquez-Martin, A., Eguiara, A., Cufi, S., Pavon, A., Menendez, J. A., Dopazo, J., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077281 · Cited by 212
Three‐dimensional cell culture models for anticancer drug screening: Worth the effort?
Verjans, E., Doijen, J., Luyten, W., Landuyt, B., & Schoofs, L. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26052 · Cited by 212 · cited 3×
“The development of standardized spheroid fabrication procedures could potentially reduce data variability and enhance the clinical significance of experimental data derived from spheroid systems [5].”
BackgroundExpansion of CTCs from early stage lung cancer patients using a microfluidic co-culture model
Zhang, Z., Shiratsuchi, H., Lin, J., Chen, G., Reddy, R. M., Azizi, E., Fouladdel, S., Chang, A. C., Lin, L., Jiang, H., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2592 · Cited by 207
Buchanan, C. F., Verbridge, S. S., Vlachos, P. P., & Rylander, M. N. (2014) · Cell Adhesion & Migration · doi:10.4161/19336918.2014.970001 · Cited by 205
Santos, J. M., Camões, S. P., Filipe, E., Cipriano, M., Barcia, R. N., Filipe, M., Teixeira, M., Simões, S., Gaspar, M., Mosqueira, D., et al. (2015) · Stem Cell Research & Therapy · doi:10.1186/s13287-015-0082-5 · Cited by 196 · cited 1×
“Spinner and rotational flasks have been commonly used [137,138] to fabricate spheroids under benign agitation.”
MethodLee, J.-H., Kim, S.-K., Khawar, I. A., Jeong, S.-Y., Chung, S., & Kuh, H.-J. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-017-0654-6 · Cited by 194 · cited 1×
“[48-53] [54-72] Spheroids in microfluidic chambers Spheroids in a hydrogel matrix”
Sabhachandani, P., Motwani, V., Cohen, N., Sarkar, S., Torchilin, V., & Konry, T. (2016) · Lab on a Chip · doi:10.1039/c5lc01139f · Cited by 193 · cited 1×
“The hydrogel droplets can be gelled by temperature, light, or ion treatments which allows a large-scale production of uniformly sized, encapsulated spheroids with minimal user-device interaction [147,169,175].”
BackgroundMicrofluidic titer plate for stratified 3D cell culture
Trietsch, S. J., Israëls, G. D., Joore, J., Hankemeier, T., & Vulto, P. (2013) · Lab on a Chip · doi:10.1039/c3lc50210d · Cited by 189
Charoen, K. M., Fallica, B., Colson, Y. L., Zaman, M. H., & Grinstaff, M. W. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2013.11.038 · Cited by 187 · cited 1×
“In general, in these tumor-on-chip systems, spheroids are embedded within a hydrogel matrix, such as collagen [28,30,31,179], Matrigel [27,32], a gelatin-based hydrogel [29,135], or alginate [119].”
BackgroundChen, Y.-A., King, A. D., Shih, H.-C., Peng, C.-C., Wu, C.-Y., Liao, W.-H., & Tung, Y.-C. (2011) · Lab on a Chip · doi:10.1039/c1lc20325h · Cited by 185
Micro-dissected tumor tissues on chip: an ex vivo method for drug testing and personalized therapy
Astolfi, M., Péant, B., Lateef, M. A., Rousset, N., Kendall-Dupont, J., Carmona, E., Monet, F., Saad, F., Provencher, D., Mes-Masson, A.-M., et al. (2016) · Lab on a Chip · doi:10.1039/c5lc01108f · Cited by 182 · cited 2×
“cultured microdissected tissues (MDTs), at dimensions below diameters of ~420 μm, on a simple microfluidic platform [198].”
BackgroundRapid formation of size-controllable multicellular spheroids via 3D acoustic tweezers
Chen, K., Wu, M., Guo, F., Li, P., Chan, C. Y., Mao, Z., Li, S., Ren, L., Zhang, R., & Huang, T. J. (2016) · Lab on a Chip · doi:10.1039/c6lc00444j · Cited by 182 · cited 1×
“Other scaffold-free methods have been recently reported—for example, the force-driven formation of spheroids by dielectrophoresis using interdigitated microelectrodes [139], the use of acoustic bulk and surface waves [140,141], and the magnetically assisted fabrication of spheroids labeled with paramagnetic particles…”
MethodCoaxial 3D bioprinting of self-assembled multicellular heterogeneous tumor fibers
Dai, X., Liu, L., Ouyang, J., Li, X., Zhang, X., Lan, Q., & Xu, T. (2017) · Scientific Reports · doi:10.1038/s41598-017-01581-y · Cited by 173
Microfluidics Enabled Bottom-Up Engineering of 3D Vascularized Tumor for Drug Discovery
Agarwal, P., Wang, H., Sun, M., Xu, J., Zhao, S., Liu, Z., Gooch, K. J., Zhao, Y., Lu, X., & He, X. (2017) · ACS Nano · doi:10.1021/acsnano.7b00824 · Cited by 168 · cited 7×
“While 2D systems were the first workhorses in cancer research, a vast body of experimental evidence confirms that the relevant features of the cancer progression, and the effectiveness of anticancer pharmaceutical compounds, cannot be properly recapitulated in 2D cell culture systems [8,57,93].”
BackgroundMethodInfluentialSimulation of complex transport of nanoparticles around a tumor using tumor-microenvironment-on-chip
Kwak, B., Ozcelikkale, A., Shin, C. S., Park, K., & Han, B. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.08.027 · Cited by 165 · cited 9×
“The authors studied the effect of size, concentration, and dynamic conditions in targeted delivery of anti-cancer compounds encapsulated in nanoparticles [28]; Figure 4b”
BackgroundMethodInfluentialCross talk between cancer and immune cells: exploring complex dynamics in a microfluidic environment
Businaro, L., De Ninno, A., Schiavoni, G., Lucarini, V., Ciasca, G., Gerardino, A., Belardelli, F., Gabriele, L., & Mattei, F. (2013) · Lab Chip · doi:10.1039/c2lc40887b · Cited by 162
Ex Vivo Tumor Culture Systems for Functional Drug Testing and Therapy Response Prediction
Meijer, T. G., Naipal, K. A., Jager, A., & van Gent, D. C. (2017) · Future Science OA · doi:10.4155/fsoa-2017-0003 · Cited by 161 · cited 1×
“Recent reviews have described the current use of microfluidics to investigate different aspects of the physiology of cancer, including (a) cell migration in the tumor microenvironment [105,109], metastasis events [110], anticancer drug screening and therapy response predictions [111], or the study of the transport of…”
BackgroundThe effects of monocytes on tumor cell extravasation in a 3D vascularized microfluidic model
Boussommier-Calleja, A., Atiyas, Y., Haase, K., Headley, M., Lewis, C., & Kamm, R. D. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2018.03.005 · Cited by 158 · cited 2×
“[30,56,62,65-68,70-72,85,189-192] [22,23,29,32,43,50,5559,63,64,165,177,194] [21,27,28,47,64]”
3D Bioprinting of Breast Cancer Models for Drug Resistance Study
Wang, Y., Shi, W., Kuss, M., Mirza, S., Qi, D., Krasnoslobodtsev, A., Zeng, J., Band, H., Band, V., & Duan, B. (2018) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.8b01277 · Cited by 157 · cited 4×
“A few bioprinting techniques have been reported for the fabrication of tumor spheroids [93,142,144,168].”
BackgroundInfluentialOptimization of liquid overlay technique to formulate heterogenic 3D co-cultures models
Costa, E. C., Gaspar, V. M., Coutinho, P., & Correia, I. J. (2014) · Biotechnology and Bioengineering · doi:10.1002/bit.25210 · Cited by 156 · cited 2×
“Adhesion can be prevented by coating the culture surface with agar [153], agarose [120,130,152,154], poly (2-hydroxyethyl methacrylate) (polyHEMA) [125], or tri-block co-polymers, such as Pluronic (F108) [26].”
BackgroundBioprinting of 3D breast epithelial spheroids for human cancer models
Swaminathan, S., Hamid, Q., Sun, W., & Clyne, A. M. (2019) · Biofabrication · doi:10.1088/1758-5090/aafc49 · Cited by 153
Hybrid collagen alginate hydrogel as a platform for 3D tumor spheroid invasion
Liu, C., Lewin Mejia, D., Chiang, B., Luker, K. E., & Luker, G. D. (2018) · Acta Biomaterialia · doi:10.1016/j.actbio.2018.06.003 · Cited by 152 · cited 1×
“Nevertheless, recent papers illustrate the use of naturally derived hydrogels for spheroid fabrication, such as collagen [122,162], Matrigel [142,143], alginate [146], and hyaluronic acid [163], and combinations of these and other materials [134,164].”
BackgroundKhoo, B. L., Grenci, G., Jing, T., Lim, Y. B., Lee, S. C., Thiery, J. P., Han, J., & Lim, C. T. (2016) · Science Advances · doi:10.1126/sciadv.1600274 · Cited by 147
Microfluidic Tumor–Vascular Model to Study Breast Cancer Cell Invasion and Intravasation
Nagaraju, S., Truong, D., Mouneimne, G., & Nikkhah, M. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201701257 · Cited by 147 · cited 1×
“[30,56,62,65-68,70-72,85,189-192] [22,23,29,32,43,50,5559,63,64,165,177,194] [21,27,28,47,64]”
Sarisozen, C., Abouzeid, A. H., & Torchilin, V. P. (2014) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2014.07.001 · Cited by 145 · cited 1×
“Adhesion can be prevented by coating the culture surface with agar [153], agarose [120,130,152,154], poly (2-hydroxyethyl methacrylate) (polyHEMA) [125], or tri-block co-polymers, such as Pluronic (F108) [26].”
BackgroundVascularized microfluidic organ-chips for drug screening, disease models and tissue engineering
Osaki, T., Sivathanu, V., & Kamm, R. D. (2018) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2018.03.011 · Cited by 141
Álvarez, M. M., Aizenberg, J., Analoui, M., Andrews, A. M., Bisker, G., Boyden, E. S., Kamm, R. D., Karp, J. M., Mooney, D. J., Öklü, R., et al. (2017) · ACS Nano · doi:10.1021/acsnano.7b01493 · Cited by 137 · cited 1×
“In particular, anticancer nanomedicines are an important trend in cancer pharmaceutical research [185].”
BackgroundSelf-citationDevelopment of an in Vitro 3D Tumor Model to Study Therapeutic Efficiency of an Anticancer Drug
Shin, C. S., Kwak, B., Han, B., & Park, K. (2013) · Molecular Pharmaceutics · doi:10.1021/mp300595a · Cited by 135 · cited 3×
“[30,56,62,65-68,70-72,85,189-192] [22,23,29,32,43,50,5559,63,64,165,177,194] [21,27,28,47,64]”
BackgroundTherapy response testing of breast cancer in a 3D high-throughput perfused microfluidic platform
Lanz, H. L., Saleh, A., Kramer, B., Cairns, J., Ng, C. P., Yu, J., Trietsch, S. J., Hankemeier, T., Joore, J., Vulto, P., et al. (2017) · BMC Cancer · doi:10.1186/s12885-017-3709-3 · Cited by 135 · cited 7×
“A mix of Matrigel and collagen I (1:1) was used as the loading matrix.”
BackgroundInfluentialDevelopment and characterization of a microfluidic model of the tumour microenvironment
Ayuso, J. M., Virumbrales-Muñoz, M., Lacueva, A., Lanuza, P. M., Checa-Chavarria, E., Botella, P., Fernández, E., Doblare, M., Allison, S. J., Phillips, R. M., et al. (2016) · Scientific Reports · doi:10.1038/srep36086 · Cited by 134 · cited 3×
“developed a polystyrene-based microfluidic device to study a tumor microenvironment in real time (Figure 5d) [36].”
BackgroundMethodInfluentialMulti-Organs-on-Chips: Towards Long-Term Biomedical Investigations
Zhao, Y., Kankala, R. K., Wang, S.-B., & Chen, A.-Z. (2019) · Molecules · doi:10.3390/molecules24040675 · Cited by 134 · cited 1×
“Human-on-chips systems that recapitulate not only the tumor niche but also one or more possible target metastasis organs connected throughout a vascular/fluidic network—will be a highly valuable tool for proper modeling of metastasis [99,223,224].”
BackgroundLive-Cell Imaging of Invasion and Intravasation in an Artificial Microvessel Platform
Wong, A. D., & Searson, P. C. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1042 · Cited by 132
Mulholland, T., McAllister, M., Patek, S., Flint, D., Underwood, M., Sim, A., Edwards, J., & Zagnoni, M. (2018) · Scientific Reports · doi:10.1038/s41598-018-33055-0 · Cited by 132
A microfluidic platform for quantitative analysis of cancer angiogenesis and intravasation
Lee, H., Park, W., Ryu, H., & Jeon, N. L. (2014) · Biomicrofluidics · doi:10.1063/1.4894595 · Cited by 130 · cited 2×
“[30,56,62,65-68,70-72,85,189-192] [22,23,29,32,43,50,5559,63,64,165,177,194] [21,27,28,47,64]”
Effect of tumor shape, size, and tissue transport properties on drug delivery to solid tumors
Sefidgar, M., Soltani, M., Raahemifar, K., Bazmara, H., Nayinian, S. M. M., & Bazargan, M. (2014) · Journal of Biological Engineering · doi:10.1186/1754-1611-8-12 · Cited by 128 · cited 1×
“For instance, recently published literature discusses the role of the size of a tumor (and the associated hypoxia levels) on its aggressiveness [81–85] and on the efficacy of drug delivery to it [84,86,87].”
BackgroundMicroengineered cancer-on-a-chip platforms to study the metastatic microenvironment
Portillo-Lara, R., & Annabi, N. (2016) · Lab on a Chip · doi:10.1039/c6lc00718j · Cited by 127 · cited 1×
“Recent reviews have described the current use of microfluidics to investigate different aspects of the physiology of cancer, including (a) cell migration in the tumor microenvironment [105,109], metastasis events [110], anticancer drug screening and therapy response predictions [111], or the study of the transport of…”
BackgroundCancer-on-a-chip systems at the frontier of nanomedicine
Zhang, Y. S., Zhang, Y.-N., & Zhang, W. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.03.011 · Cited by 127 · cited 2×
“As previously stated, in this review, we focus on the recent development of in vitro microfluidic solid-tumor platforms, or tumor-on-chip systems [8,88,113].”
BackgroundSelf-citation3D spherical microtissues and microfluidic technology for multi-tissue experiments and analysis
Kim, J.-Y., Fluri, D. A., Marchan, R., Boonen, K., Mohanty, S., Singh, P., Hammad, S., Landuyt, B., Hengstler, J. G., Kelm, J. M., et al. (2015) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2015.01.003 · Cited by 126
Kim, J. A., Choi, J., Kim, M., Rhee, W. J., Son, B., Jung, H.-K., & Park, T. H. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.07.056 · Cited by 126 · cited 1×
“Other scaffold-free methods have been recently reported—for example, the force-driven formation of spheroids by dielectrophoresis using interdigitated microelectrodes [139], the use of acoustic bulk and surface waves [140,141], and the magnetically assisted fabrication of spheroids labeled with paramagnetic particles…”
MethodImpact of the spheroid model complexity on drug response
Hoffmann, O. I., Ilmberger, C., Magosch, S., Joka, M., Jauch, K.-W., & Mayer, B. (2015) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2015.02.029 · Cited by 125 · cited 1×
“Despite their simplicity, they hold great promise for the recapitulation of solid tumors in many relevant aspects [22,29,116,117].”
BackgroundHigh-throughput acoustofluidic fabrication of tumor spheroids
Chen, B., Wu, Y., Ao, Z., Cai, H., Nunez, A., Liu, Y., Foley, J., Nephew, K., Lu, X., & Guo, F. (2019) · Lab on a Chip · doi:10.1039/c9lc00135b · Cited by 124
An end-user perspective on Organ-on-a-Chip: Assays and usability aspects
Junaid, A., Mashaghi, A., Hankemeier, T., & Vulto, P. (2017) · Current Opinion in Biomedical Engineering · doi:10.1016/j.cobme.2017.02.002 · Cited by 123 · cited 1×
“For example, the fabrication of microfluidic devices is still a task that requires skill and experience [12,201].”
BackgroundA novel 3D breast-cancer-on-chip platform for therapeutic evaluation of drug delivery systems
Chen, Y., Gao, D., Wang, Y., Lin, S., & Jiang, Y. (2018) · Analytica Chimica Acta · doi:10.1016/j.aca.2018.06.038 · Cited by 122 · cited 4×
“[30,56,62,65-68,70-72,85,189-192] [22,23,29,32,43,50,5559,63,64,165,177,194] [21,27,28,47,64]”
BackgroundMethodInfluentialCancer Cells Regulate Biomechanical Properties of Human Microvascular Endothelial Cells
Mierke, C. T. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.256172 · Cited by 118 · cited 1×
“[64] studied the EPR effect [199] in a tumor-on-chip system and showed that endothelial cells co-cultured with metastatic MDA-MB-231 cancer cells formed leakier vascular channels than those co-cultured with non-metastatic MCF-7 cancer cells.”
BackgroundLing, K., Huang, G., Liu, J., Zhang, X., Ma, Y., Lu, T., & Xu, F. (2015) · Engineering · doi:10.15302/j-eng-2015062 · Cited by 117 · cited 1×
“A few bioprinting techniques have been reported for the fabrication of tumor spheroids [93,142,144,168].”
BackgroundSiltanen, C. A., Yaghoobi, M., Haque, A., You, J., Lowen, J. M., Soleimani, M., & Revzin, A. (2016) · Acta Biomaterialia · doi:10.1016/j.actbio.2016.01.012 · Cited by 116 · cited 1×
“Nevertheless, recent papers illustrate the use of naturally derived hydrogels for spheroid fabrication, such as collagen [122,162], Matrigel [142,143], alginate [146], and hyaluronic acid [163], and combinations of these and other materials [134,164].”
BackgroundBruce, A., Evans, R., Mezan, R., Shi, L., Moses, B. S., Martin, K. H., Gibson, L. F., & Yang, Y. (2015) · PLOS ONE · doi:10.1371/journal.pone.0140506 · Cited by 112 · cited 4×
“[49] to recreate a bone marrow microenvironment and study acute lymphoblastic leukemia (ALL): (i) schematic representation, (ii) actual image, (iii) and detail of the post array within the device.”
BackgroundInfluentialGioiella, F., Urciuolo, F., Imparato, G., Brancato, V., & Netti, P. A. (2016) · Advanced Healthcare Materials · doi:10.1002/adhm.201600772 · Cited by 112 · cited 5×
“Taken from reference [33]; (b) On-chip activation of stromal tissue by crosstalk with cancerous tissue [35]: (i) schematic representation of the device and (ii) actual micrographs of normal cells (expressing GFP) and cancer cells (expressing RFP).”
BackgroundInfluentialA 3D printed microfluidic perfusion device for multicellular spheroid cultures
Ong, L. J. Y., Islam, A., DasGupta, R., Iyer, N. G., Leo, H. L., & Toh, Y.-C. (2017) · Biofabrication · doi:10.1088/1758-5090/aa8858 · Cited by 112 · cited 1×
“Some recent examples illustrate this in the very context of tumor-on-chip applications [204].”
BackgroundEffect of tumor shape and size on drug delivery to solid tumors
Soltani, M., & Chen, P. (2012) · Journal of Biological Engineering · doi:10.1186/1754-1611-6-4 · Cited by 110
Bai, J., Adriani, G., Dang, T.-M., Tu, T.-Y., Leong Penny, H.-X., Wong, S.-C., Kamm, R. D., & Thiery, J.-P. (2015) · Oncotarget · doi:10.18632/oncotarget.4716 · Cited by 110
Finding the tumor copycat: Therapy fails, patients don’t
Ellis, L. M., & Fidler, I. J. (2010) · Nature Medicine · doi:10.1038/nm0910-974 · Cited by 109
Anticancer drug discovery using multicellular tumor spheroid models
Zanoni, M., Pignatta, S., Arienti, C., Bonafè, M., & Tesei, A. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1570129 · Cited by 106
A microfluidic platform for chemoresistive testing of multicellular pleural cancer spheroids
Ruppen, J., Cortes-Dericks, L., Marconi, E., Karoubi, G., Schmid, R. A., Peng, R., Marti, T. M., & Guenat, O. T. (2014) · Lab Chip · doi:10.1039/c3lc51093j · Cited by 105 · cited 6×
“The end result is a reduction in the consumption of reagents, a higher density of cells, a higher cell to fluid ratio, and real-time control of delivery of nutrients and reagents [20,124,145,173,174].”
BackgroundMethodInfluentialA 3D human renal cell carcinoma-on-a-chip for the study of tumor angiogenesis
Miller, C. P., Tsuchida, C., Zheng, Y., Himmelfarb, J., & Akilesh, S. (2018) · Neoplasia · doi:10.1016/j.neo.2018.02.011 · Cited by 105 · cited 2×
“Several other papers have illustrated the use of CFD to improve the hydraulic design of lab-on-chip systems [221] and organ-on-chip systems [69,222], including tumor-on-chip devices.”
BackgroundTang, Y., Soroush, F., Sheffield, J. B., Wang, B., Prabhakarpandian, B., & Kiani, M. F. (2017) · Scientific Reports · doi:10.1038/s41598-017-09815-9 · Cited by 102 · cited 5×
“Rx-3 Tumor invasion, intravasation & extravasation [64] EPR effect Pharmacological testing (a) (b)”
BackgroundInfluentialPiotrowski-Daspit, A. S., Tien, J., & Nelson, C. M. (2016) · Integrative Biology · doi:10.1039/c5ib00282f · Cited by 101
Tumor spheroid assembly on hyaluronic acid-based structures: A review
Carvalho, M. P., Costa, E. C., Miguel, S. P., & Correia, I. J. (2016) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2016.05.005 · Cited by 100 · cited 1×
“Nevertheless, recent papers illustrate the use of naturally derived hydrogels for spheroid fabrication, such as collagen [122,162], Matrigel [142,143], alginate [146], and hyaluronic acid [163], and combinations of these and other materials [134,164].”
BackgroundSun, Q., Tan, S. H., Chen, Q., Ran, R., Hui, Y., Chen, D., & Zhao, C.-X. (2018) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.8b00904 · Cited by 100 · cited 3×
“Recent reports have described the high-throughput and continuous fabrication of tumor spheroids of tunable size by microfluidic means [57,119,169,170].”
BackgroundGeneration and manipulation of magnetic multicellular spheroids
Ho, V. H. B., Müller, K. H., Barcza, A., Chen, R., & Slater, N. K. H. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2009.12.047 · Cited by 99 · cited 1×
“Other scaffold-free methods have been recently reported—for example, the force-driven formation of spheroids by dielectrophoresis using interdigitated microelectrodes [139], the use of acoustic bulk and surface waves [140,141], and the magnetically assisted fabrication of spheroids labeled with paramagnetic particles…”
MethodLim, W., & Park, S. (2018) · Molecules · doi:10.3390/molecules23123355 · Cited by 99 · cited 3×
“[30,56,62,65-68,70-72,85,189-192] [22,23,29,32,43,50,5559,63,64,165,177,194] [21,27,28,47,64]”
BackgroundMethodStretching Fibroblasts Remodels Fibronectin and Alters Cancer Cell Migration
Ao, M., Brewer, B. M., Yang, L., Franco Coronel, O. E., Hayward, S. W., Webb, D. J., & Li, D. (2015) · Scientific Reports · doi:10.1038/srep08334 · Cited by 96
A Microvascularized Tumor-mimetic Platform for Assessing Anti-cancer Drug Efficacy
Pradhan, S., Smith, A. M., Garson, C. J., Hassani, I., Seeto, W. J., Pant, K., Arnold, R. D., Prabhakarpandian, B., & Lipke, E. A. (2018) · Scientific Reports · doi:10.1038/s41598-018-21075-9 · Cited by 96 · cited 1×
“[48-53] [54-72] Spheroids in microfluidic chambers Spheroids in a hydrogel matrix”
Mannino, R. G., Santiago-Miranda, A. N., Pradhan, P., Qiu, Y., Mejias, J. C., Neelapu, S. S., Roy, K., & Lam, W. A. (2017) · Lab on a Chip · doi:10.1039/c6lc01204c · Cited by 89 · cited 6×
“In another study [54], A20 cell line mouse B-cell lymphoma was used to replicate diffuse large B-cell lymphoma (DLBCL), and mouse lung microvascular endothelial cells (MLMVECs) were used as endothelial cells.”
BackgroundMethodInfluentialMass fabrication of uniform sized 3D tumor spheroid using high-throughput microfluidic system
Kwak, B., Lee, Y., Lee, J. H., Lee, S., & Lim, J. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.02.029 · Cited by 88 · cited 2×
“Recent reports have described the high-throughput and continuous fabrication of tumor spheroids of tunable size by microfluidic means [57,119,169,170].”
BackgroundOzcelikkale, A., Moon, H., Linnes, M., & Han, B. (2017) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1460 · Cited by 87 · cited 1×
“Recent reviews have described the current use of microfluidics to investigate different aspects of the physiology of cancer, including (a) cell migration in the tumor microenvironment [105,109], metastasis events [110], anticancer drug screening and therapy response predictions [111], or the study of the transport of…”
BackgroundSong, J., Miermont, A., Lim, C. T., & Kamm, R. D. (2018) · Scientific Reports · doi:10.1038/s41598-018-36381-5 · Cited by 87 · cited 1×
“[30,56,62,65-68,70-72,85,189-192] [22,23,29,32,43,50,5559,63,64,165,177,194] [21,27,28,47,64]”
Sabhachandani, P., Sarkar, S., Mckenney, S., Ravi, D., Evens, A. M., & Konry, T. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.12.010 · Cited by 87 · cited 1×
“The end result is a reduction in the consumption of reagents, a higher density of cells, a higher cell to fluid ratio, and real-time control of delivery of nutrients and reagents [20,124,145,173,174].”
BackgroundFu, C.-Y., Tseng, S.-Y., Yang, S.-M., Hsu, L., Liu, C.-H., & Chang, H.-Y. (2014) · Biofabrication · doi:10.1088/1758-5082/6/1/015009 · Cited by 86 · cited 1×
“The end result is a reduction in the consumption of reagents, a higher density of cells, a higher cell to fluid ratio, and real-time control of delivery of nutrients and reagents [20,124,145,173,174].”
BackgroundMirab, F., Kang, Y. J., & Majd, S. (2019) · PLOS ONE · doi:10.1371/journal.pone.0211078 · Cited by 86 · cited 1×
“Adhesion can be prevented by coating the culture surface with agar [153], agarose [120,130,152,154], poly (2-hydroxyethyl methacrylate) (polyHEMA) [125], or tri-block co-polymers, such as Pluronic (F108) [26].”
Background3D In Vitro Model for Breast Cancer Research Using Magnetic Levitation and Bioprinting Method
Leonard, F., & Godin, B. (2016) · Methods in Molecular Biology · doi:10.1007/978-1-4939-3444-7_21 · Cited by 85 · cited 1×
“A few bioprinting techniques have been reported for the fabrication of tumor spheroids [93,142,144,168].”
BackgroundLiu, J., Kuznetsova, L. A., Edwards, G. O., Xu, J., Ma, M., Purcell, W. M., Jackson, S. K., & Coakley, W. T. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21345 · Cited by 83 · cited 1×
“Other scaffold-free methods have been recently reported—for example, the force-driven formation of spheroids by dielectrophoresis using interdigitated microelectrodes [139], the use of acoustic bulk and surface waves [140,141], and the magnetically assisted fabrication of spheroids labeled with paramagnetic particles…”
MethodOrgan-Tumor-on-a-Chip for Chemosensitivity Assay: A Critical Review
Kashaninejad, N., Nikmaneshi, M., Moghadas, H., Kiyoumarsi Oskouei, A., Rismanian, M., Barisam, M., Saidi, M., & Firoozabadi, B. (2016) · Micromachines · doi:10.3390/mi7080130 · Cited by 79
Safety in analytical laboratories: basic safety in volumetric analysis
(1977) · Proceedings of the Analytical Division of the Chemical Society · doi:10.1039/ad9771400225 · Cited by 79
Wang, X.-Y., Pei, Y., Xie, M., Jin, Z.-H., Xiao, Y.-S., Wang, Y., Zhang, L.-N., Li, Y., & Huang, W.-H. (2015) · Lab on a Chip · doi:10.1039/c4lc00973h · Cited by 77 · cited 1×
“[30,56,62,65-68,70-72,85,189-192] [22,23,29,32,43,50,5559,63,64,165,177,194] [21,27,28,47,64]”
Montanez-Sauri, S. I., Sung, K. E., Berthier, E., & Beebe, D. J. (2013) · Integrative Biology · doi:10.1039/c3ib20225a · Cited by 77 · cited 1×
“[48-53] [54-72] Spheroids in microfluidic chambers Spheroids in a hydrogel matrix”
Lee, B. H., Kim, M. H., Lee, J. H., Seliktar, D., Cho, N.-J., & Tan, L. P. (2015) · PLOS ONE · doi:10.1371/journal.pone.0118123 · Cited by 75 · cited 2×
“[30,56,62,65-68,70-72,85,189-192] [22,23,29,32,43,50,5559,63,64,165,177,194] [21,27,28,47,64]”
BackgroundHuang, K., Boerhan, R., Liu, C., & Jiang, G. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00726 · Cited by 74
Alginate-based microfluidic system for tumor spheroid formation and anticancer agent screening
Chen, M. C. W., Gupta, M., & Cheung, K. C. (2010) · Biomedical Microdevices · doi:10.1007/s10544-010-9417-2 · Cited by 73 · cited 1×
“Although other methods have been proposed [150,151,171,172], the generation of spheroids by microfluidic techniques is done mainly by approaches based on micro-molding and micro-droplets.”
MethodOzkan, A., Ghousifam, N., Hoopes, P. J., Yankeelov, T. E., & Rylander, M. N. (2019) · Biotechnology and Bioengineering · doi:10.1002/bit.26919 · Cited by 73 · cited 4×
“aimed at a partial recreation of the interplay between healthy or tumorigenic liver and breast tumor niches throughout the development of a simple dual organ-on-chip [55].”
InfluentialThree-Dimensional Cell Culture and Drug Testing in a Microfluidic Sidewall-Attached Droplet Array
Zhao, S.-P., Ma, Y., Lou, Q., Zhu, H., Yang, B., & Fang, Q. (2017) · Analytical Chemistry · doi:10.1021/acs.analchem.7b02267 · Cited by 72 · cited 1×
“[30,56,62,65-68,70-72,85,189-192] [22,23,29,32,43,50,5559,63,64,165,177,194] [21,27,28,47,64]”
Accelerating anticancer drug development — opportunities and trade-offs
Nass, S. J., Rothenberg, M. L., Pentz, R. D., Hricak, H., Abernethy, A. P., Anderson, K. C., Gee, A. W., Harvey, R. D., Piantadosi, S., Bertagnolli, M. M., et al. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0102-3 · Cited by 72
Watanabe, T., Motohiro, I., & Ono, T. (2019) · Langmuir · doi:10.1021/acs.langmuir.8b04169 · Cited by 71 · cited 1×
“The hydrogel droplets can be gelled by temperature, light, or ion treatments which allows a large-scale production of uniformly sized, encapsulated spheroids with minimal user-device interaction [147,169,175].”
BackgroundBai, J., Tu, T.-Y., Kim, C., Thiery, J. P., & Kamm, R. D. (2015) · Oncotarget · doi:10.18632/oncotarget.5464 · Cited by 70 · cited 2×
“[30,56,62,65-68,70-72,85,189-192] [22,23,29,32,43,50,5559,63,64,165,177,194] [21,27,28,47,64]”
Organ‐on‐a‐Chip for Cancer and Immune Organs Modeling
Sun, W., Luo, Z., Lee, J., Kim, H., Lee, K., Tebon, P., Feng, Y., Dokmeci, M. R., Sengupta, S., & Khademhosseini, A. (2019) · Advanced Healthcare Materials · doi:10.1002/adhm.201900754 · Cited by 70
A bladder cancer microenvironment simulation system based on a microfluidic co-culture model
Liu, P.-F., Cao, Y.-W., Zhang, S.-D., Zhao, Y., Liu, X.-G., Shi, H.-Q., Hu, K.-Y., Zhu, G.-Q., Ma, B., & Niu, H.-T. (2015) · Oncotarget · doi:10.18632/oncotarget.6070 · Cited by 68
Three-Dimensional Breast Cancer Models Mimic Hallmarks of Size-Induced Tumor Progression
Singh, M., Mukundan, S., Jaramillo, M., Oesterreich, S., & Sant, S. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2304 · Cited by 68 · cited 1×
“When a tumor exceeds a critical diameter of 200 μm, hypoxia develops at its central core, and a complex biochemical cascade commands vascularization to start [126,184].”
Background3D printing for the development of in vitro cancer models
Samavedi, S., & Joy, N. (2017) · Current Opinion in Biomedical Engineering · doi:10.1016/j.cobme.2017.06.003 · Cited by 67 · cited 1×
“approaches [210–212] will certainly simplify the fabrication of complex tumorous tissues [206,213].”
BackgroundCampillo, N., Falcones, B., Otero, J., Colina, R., Gozal, D., Navajas, D., Farré, R., & Almendros, I. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00043 · Cited by 66
Study on Invadopodia Formation for Lung Carcinoma Invasion with a Microfluidic 3D Culture Device
Wang, S., Li, E., Gao, Y., Wang, Y., Guo, Z., He, J., Zhang, J., Gao, Z., & Wang, Q. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056448 · Cited by 65
Modeling of cancer metastasis and drug resistance via biomimetic nano-cilia and microfluidics
Kuo, C.-T., Chiang, C.-L., Chang, C.-H., Liu, H.-K., Huang, G.-S., Huang, R. Y.-J., Lee, H., Huang, C.-S., & Wo, A. M. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2013.11.008 · Cited by 65 · cited 2×
“Several recent contributions demonstrate the use of CFD simulations to study the transport of materials near a tumor in tumor-on-chip systems [26,56] or in vivo [220].”
BackgroundA Hollow Sphere Soft Lithography Approach for Long-Term Hanging Drop Methods
Lee, W. G., Ortmann, D., Hancock, M. J., Bae, H., & Khademhosseini, A. (2010) · Tissue Engineering Part C: Methods · doi:10.1089/ten.tec.2009.0248 · Cited by 62 · cited 1×
“developed a long-term hanging drop method that used a soft lithographic approach [128].”
MethodThree Dimensional Microfluidic Cell Arrays for ex Vivo Drug Screening with Mimicked Vascular Flow
Dereli-Korkut, Z., Akaydin, H. D., Ahmed, A. H. R., Jiang, X., & Wang, S. (2014) · Analytical Chemistry · doi:10.1021/ac403899j · Cited by 62 · cited 1×
“[48-53] [54-72] Spheroids in microfluidic chambers Spheroids in a hydrogel matrix”
A microfluidic model for organ-specific extravasation of circulating tumor cells
Riahi, R., Yang, Y. L., Kim, H., Jiang, L., Wong, P. K., & Zohar, Y. (2014) · Biomicrofluidics · doi:10.1063/1.4868301 · Cited by 60 · cited 1×
“[30,56,62,65-68,70-72,85,189-192] [22,23,29,32,43,50,5559,63,64,165,177,194] [21,27,28,47,64]”
Adding the ‘heart’ to hanging drop networks for microphysiological multi-tissue experiments
Rismani Yazdi, S., Shadmani, A., Bürgel, S. C., Misun, P. M., Hierlemann, A., & Frey, O. (2015) · Lab on a Chip · doi:10.1039/c5lc01000d · Cited by 60 · cited 2×
“Although other methods have been proposed [150,151,171,172], the generation of spheroids by microfluidic techniques is done mainly by approaches based on micro-molding and micro-droplets.”
MethodSteuperaert, M., Debbaut, C., Carlier, C., Wever, O. D., Descamps, B., Vanhove, C., Ceelen, W. P., & Segers, P. (2019) · Drug Delivery · doi:10.1080/10717544.2019.1588423 · Cited by 59 · cited 1×
“Several recent contributions demonstrate the use of CFD simulations to study the transport of materials near a tumor in tumor-on-chip systems [26,56] or in vivo [220].”
BackgroundDubiak-Szepietowska, M., Karczmarczyk, A., Jönsson‐Niedziółka, M., Winckler, T., & Feller, K. ‐. (2016) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2016.01.016 · Cited by 58 · cited 6×
“A mix of Matrigel and collagen I (1:1) was used as the loading matrix.”
BackgroundInfluentialSelf‐Assembling Peptide Gels for 3D Prostate Cancer Spheroid Culture
Hainline, K. M., Gu, F., Handley, J. F., Tian, Y. F., Wu, Y., de Wet, L., Vander Griend, D. J., & Collier, J. H. (2019) · Macromolecular Bioscience · doi:10.1002/mabi.201800249 · Cited by 56
Agarose multi-wells for tumour spheroid formation and anti-cancer drug test
Tang, Y., Liu, J., & Chen, Y. (2016) · Microelectronic Engineering · doi:10.1016/j.mee.2016.03.009 · Cited by 54
Santiago, G. T., Álvarez, M. M., Samandari, M., Prakash, G., Chandrabhatla, G., Rellstab‐Sánchez, P. I., Byambaa, B., Abadi, P. P. S. S., Mandla, S., Avery, R. K., et al. (2018) · Materials Horizons · doi:10.1039/c8mh00344k · Cited by 54 · cited 1×
“used chaotic bioprinting, a microfabrication technique based on the use of chaotic flows, to fabricate a construct containing a high amount of interface between cancerous and normal cells [210].”
MethodSelf-citationHeylman, C., Sobrino, A., Shirure, V. S., Hughes, C. C., & George, S. C. (2014) · Experimental Biology and Medicine · doi:10.1177/1535370214525295 · Cited by 53 · cited 6×
“This strongly suggests that the current in vitro and preclinical models are not reliable predictors of the actual in vivo efficacy and toxicity of anticancer drugs in humans [8] (Figure 1a).”
BackgroundInfluentialA microfluidic co-culture system to monitor tumor-stromal interactions on a chip
Menon, N. V., Chuah, Y. J., Cao, B., Lim, M., & Kang, Y. (2014) · Biomicrofluidics · doi:10.1063/1.4903762 · Cited by 53 · cited 1×
“[30,56,62,65-68,70-72,85,189-192] [22,23,29,32,43,50,5559,63,64,165,177,194] [21,27,28,47,64]”
Han, B., Qu, C., Park, K., Konieczny, S. F., & Korc, M. (2016) · Cancer Letters · doi:10.1016/j.canlet.2015.12.003 · Cited by 53 · cited 2×
“Modified from Han et al., 2016 [19].”
BackgroundXiang, X., Phung, Y., Feng, M., Nagashima, K., Zhang, J., Broaddus, V. C., Hassan, R., FitzGerald, D., & Ho, M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0014640 · Cited by 51 · cited 2×
“Adhesion can be prevented by coating the culture surface with agar [153], agarose [120,130,152,154], poly (2-hydroxyethyl methacrylate) (polyHEMA) [125], or tri-block co-polymers, such as Pluronic (F108) [26].”
BackgroundMicrofluidic experimental platform for producing size-controlled three-dimensional spheroids
Ota, H., & Miki, N. (2011) · Sensors and Actuators A Physical · doi:10.1016/j.sna.2011.03.051 · Cited by 50 · cited 1×
“Although other methods have been proposed [150,151,171,172], the generation of spheroids by microfluidic techniques is done mainly by approaches based on micro-molding and micro-droplets.”
MethodChemotaxis-driven assembly of endothelial barrier in a tumor-on-a-chip platform
Aung, A., Theprungsirikul, J., Lim, H. L., & Varghese, S. (2016) · Lab on a Chip · doi:10.1039/c6lc00184j · Cited by 50 · cited 5×
“[50] developed a tumorous microtissue encapsulated by an endothelial barrier composed of HUVECs.”
BackgroundMethodInfluentialA Microdevice Platform Recapitulating Hypoxic Tumor Microenvironments
Ando, Y., Ta, H. P., Yen, D. P., Lee, S., Raola, S., & Shen, K. (2017) · Scientific Reports · doi:10.1038/s41598-017-15583-3 · Cited by 50
Lammel, T., Tsoukatou, G., Jellinek, J., & Sturve, J. (2018) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2018.10.009 · Cited by 50 · cited 1×
“Spinner and rotational flasks have been commonly used [137,138] to fabricate spheroids under benign agitation.”
MethodDigital microfluidics for spheroid-based invasion assays
Bender, B. F., Aijian, A. P., & Garrell, R. L. (2016) · Lab on a Chip · doi:10.1039/c5lc01569c · Cited by 49 · cited 1×
“In general, in these tumor-on-chip systems, spheroids are embedded within a hydrogel matrix, such as collagen [28,30,31,179], Matrigel [27,32], a gelatin-based hydrogel [29,135], or alginate [119].”
BackgroundCell migration in microengineered tumor environments
Um, E., Oh, J. M., Granick, S., & Cho, Y. (2017) · Lab on a Chip · doi:10.1039/c7lc00555e · Cited by 47 · cited 1×
“Recent reviews have described the current use of microfluidics to investigate different aspects of the physiology of cancer, including (a) cell migration in the tumor microenvironment [105,109], metastasis events [110], anticancer drug screening and therapy response predictions [111], or the study of the transport of…”
BackgroundTumor Bioengineering Using a Transglutaminase Crosslinked Hydrogel
Fang, J. Y., Tan, S., Yang, Z. G., Tayag, C., & Han, B. (2014) · PLoS ONE · doi:10.1371/journal.pone.0105616 · Cited by 46 · cited 1×
“Nevertheless, recent papers illustrate the use of naturally derived hydrogels for spheroid fabrication, such as collagen [122,162], Matrigel [142,143], alginate [146], and hyaluronic acid [163], and combinations of these and other materials [134,164].”
BackgroundBiofabrication strategies for creating microvascular complexity
Clyne, A. M., Swaminathan, S., & Lantada, A. D. (2019) · Biofabrication · doi:10.1088/1758-5090/ab0621 · Cited by 46
Rethinking liquid biopsy: Microfluidic assays for mobile tumor cells in human body fluids
Neoh, K. H., Hassan, A. A., Chen, A., Sun, Y., Liu, P., Xu, K.-F., Wong, A. S. T., & Han, R. P. S. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2017.10.006 · Cited by 44
Gut-microbiota-on-a-chip: an enabling field for physiological research
Trujillo-de Santiago, G., Lobo-Zegers, M. J., Montes-Fonseca, S. L., Zhang, Y. S., & Alvarez, M. M. (2018) · Microphysiological Systems · doi:10.21037/mps.2018.09.01 · Cited by 43
Self-citationProteomics analysis of E-cadherin knockdown in epithelial breast cancer cells
Vergara, D., Simeone, P., Latorre, D., Cascione, F., Leporatti, S., Trerotola, M., Giudetti, A. M., Capobianco, L., Lunetti, P., Rizzello, A., et al. (2015) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2014.10.034 · Cited by 41 · cited 1×
“For example, the role of E-cadherin as a suppressor of cancer invasiveness has been widely cited [75,76].”
Background
Cited by
Nanomedicine in cancer therapy
Fan, D., Cao, Y., Cao, M., Wang, Y., Cao, Y., & Gong, T. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01536-y · Cited by 878
Organoid and Spheroid Tumor Models: Techniques and Applications
Gunti, S., Hoke, A. T. K., Vu, K. P., & London, N. R. (2021) · Cancers · doi:10.3390/cancers13040874 · Cited by 479
“However, a majority of these studies utilized cancer cell lines to co str ct s eroi s a o ly fe studies used patient-derived tumor tissue [74].”
BackgroundA role for microfluidic systems in precision medicine
Ayuso, J. M., Virumbrales-Muñoz, M., Lang, J. M., & Beebe, D. J. (2022) · Nature Communications · doi:10.1038/s41467-022-30384-7 · Cited by 216
Neufeld, L., Yeini, E., Reisman, N., Shtilerman, Y., Ben-Shushan, D., Pozzi, S., Madi, A., Tiram, G., Eldar-Boock, A., Ferber, S., et al. (2021) · Science Advances · doi:10.1126/sciadv.abi9119 · Cited by 189
Bioengineered 3D models of human pancreatic cancer recapitulate in vivo tumour biology
Osuna de la Peña, D., Trabulo, S. M. D., Collin, E., Liu, Y., Sharma, S., Tatari, M., Behrens, D., Erkan, M., Lawlor, R. T., Scarpa, A., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25921-9 · Cited by 138
Metadata
- Authors
- Trujillo-de Santiago, G., Flores-Garza, B. G., Tavares-Negrete, J. A., Lara-Mayorga, I. M., González-Gamboa, I., Zhang, Y. S., Rojas-Martínez, A., Ortiz-López, R., & Álvarez, M. M.
- Affiliations
- Centro de Biotecnología-FEMSA, Tecnologico de Monterrey, Monterrey, Nuevo León CP 64849, Mexico
- Tecnológico de Monterrey (MX)
- Brigham and Women's Hospital (US)
- Centro de Investigación y Transferencia en Salud, Hospital San José, Tecnologico de Monterrey, Monterrey, Nuevo León CP 64849, Mexico
- Corresponding author
- Álvarez, Mario Moisés
- ORCID
- Venue
- Materials
- Publisher
- MDPI AG
- Published
- 2019-09-11
- Volume
- 12
- Issue
- 18
- Pages
- 2945
- ISSN
- 1996-1944 (ISSN-L)
- PMC
- PMC6766252
- OpenAlex
- W2972592345
- Cited by
- 184
- References
- 231
- Citations by year
- 2026: 12 · 2025: 17 · 2024: 47 · 2023: 21 · 2022: 25 · 2021: 47 · 2020: 13 · 2019: 2
- FWCI
- 1.76
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Materials (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Consejo Nacional de Ciencia y Tecnología (SNI256730, SNI 26048)
- Tecnologico de Monterrey (002EI CIN01)
- Topics
- Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
- Physical Sciences › Engineering › Biomedical Engineering › Microfluidic and Capillary Electrophoresis Applications
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- tumor-on-a-chip, microfluidics, solid tumors, tumor microenvironment, 3D tumor culture, anticancer drug screening, precision oncology, 3D bioprinting, computational fluid dynamics, high-throughput omics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.